WO2018070069A1 - 医薬 - Google Patents
医薬 Download PDFInfo
- Publication number
- WO2018070069A1 WO2018070069A1 PCT/JP2017/015227 JP2017015227W WO2018070069A1 WO 2018070069 A1 WO2018070069 A1 WO 2018070069A1 JP 2017015227 W JP2017015227 W JP 2017015227W WO 2018070069 A1 WO2018070069 A1 WO 2018070069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lag
- protein
- derived peptide
- cancer
- cells
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 229940079593 drug Drugs 0.000 title description 6
- 102000017578 LAG3 Human genes 0.000 claims abstract description 125
- 101150030213 Lag3 gene Proteins 0.000 claims abstract description 123
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims abstract description 20
- 239000003970 toll like receptor agonist Substances 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 240
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 190
- 201000011510 cancer Diseases 0.000 claims description 183
- 108091007433 antigens Proteins 0.000 claims description 108
- 102000036639 antigens Human genes 0.000 claims description 108
- 239000000427 antigen Substances 0.000 claims description 81
- 239000002671 adjuvant Substances 0.000 claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 230000028993 immune response Effects 0.000 claims description 58
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 51
- 102100032530 Glypican-3 Human genes 0.000 claims description 51
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 51
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 51
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 51
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 43
- 108700002563 poly ICLC Proteins 0.000 claims description 34
- 239000012648 POLY-ICLC Substances 0.000 claims description 23
- 229940115270 poly iclc Drugs 0.000 claims description 23
- 229940022399 cancer vaccine Drugs 0.000 claims description 19
- 238000009566 cancer vaccine Methods 0.000 claims description 19
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- 108020001507 fusion proteins Proteins 0.000 claims description 15
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940124122 Toll-like receptor 3 agonist Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000004027 cell Anatomy 0.000 description 107
- 239000000556 agonist Substances 0.000 description 101
- 241000699666 Mus <mouse, genus> Species 0.000 description 87
- 102000002689 Toll-like receptor Human genes 0.000 description 60
- 108020000411 Toll-like receptor Proteins 0.000 description 60
- 150000001413 amino acids Chemical group 0.000 description 45
- 239000000126 substance Substances 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 34
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 29
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 29
- 210000002865 immune cell Anatomy 0.000 description 24
- 101800001318 Capsid protein VP4 Proteins 0.000 description 20
- 230000008859 change Effects 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 19
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 15
- 210000001165 lymph node Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 101800001271 Surface protein Proteins 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 11
- 210000005007 innate immune system Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- -1 phospho Chemical class 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 8
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 8
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 8
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 8
- 229940056913 eftilagimod alfa Drugs 0.000 description 8
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 7
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 7
- 102100034256 Mucin-1 Human genes 0.000 description 7
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 6
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 6
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 6
- 108010028921 Lipopeptides Proteins 0.000 description 6
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 6
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004970 cd4 cell Anatomy 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 201000004101 esophageal cancer Diseases 0.000 description 6
- 229960002751 imiquimod Drugs 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 5
- 108010075704 HLA-A Antigens Proteins 0.000 description 5
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 5
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 5
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 5
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 5
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002458 cell surface marker Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- OKYYOKGIPDRZJA-CPSXWDTOSA-N chembl2103792 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 OKYYOKGIPDRZJA-CPSXWDTOSA-N 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010040721 Flagellin Proteins 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 3
- 229920000392 Zymosan Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 210000001099 axilla Anatomy 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000037453 T cell priming Effects 0.000 description 2
- 229940124614 TLR 8 agonist Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229950001741 agatolimod Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- QUWFSKKBMDKAHK-SBOJBMMISA-A chembl2103793 Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 QUWFSKKBMDKAHK-SBOJBMMISA-A 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000001571 immunoadjuvant effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- FEFIBEHSXLKJGI-UHFFFAOYSA-N methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7h-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate Chemical compound C12=NC(OCCCC)=NC(N)=C2NC(=O)N1CCCN(CC=1C=C(CC(=O)OC)C=CC=1)CCCN1CCOCC1 FEFIBEHSXLKJGI-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- YSQDQEOIFWWVHA-UHFFFAOYSA-A promune Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 YSQDQEOIFWWVHA-UHFFFAOYSA-A 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- REEGNIYAMZUTIO-MGSMBCBTSA-N (2s)-2-[[(3r)-3-decanoyloxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decanoyloxytetradecanoyl]amino]-4-[(3r)-3-decanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OC(=O)CCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC REEGNIYAMZUTIO-MGSMBCBTSA-N 0.000 description 1
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 description 1
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 description 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100040079 A-kinase anchor protein 4 Human genes 0.000 description 1
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010079458 CBLB502 Proteins 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 101150056960 Casp8 gene Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 101100385253 Chiloscyllium indicum GM1 gene Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100095895 Drosophila melanogaster sle gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150049307 EEF1A2 gene Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102100037074 Ellis-van Creveld syndrome protein Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000881890 Homo sapiens Ellis-van Creveld syndrome protein Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 1
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102100035135 Limbin Human genes 0.000 description 1
- 108050003065 Limbin Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101800000212 P1A protein Proteins 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 102100026181 Placenta-specific protein 1 Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 description 1
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100039490 X antigen family member 1 Human genes 0.000 description 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 description 1
- HOOMGTNENMZAFP-NYNCVSEMSA-N [(2r,3r,5s)-2-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1C[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 HOOMGTNENMZAFP-NYNCVSEMSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000020420 bandung Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 229950009493 entolimod Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 229940040731 human interleukin-12 Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- OAGNPTDOULFGJY-UHFFFAOYSA-N mercury;phenyl nitrate Chemical compound [Hg].[O-][N+](=O)OC1=CC=CC=C1 OAGNPTDOULFGJY-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 101150050955 stn gene Proteins 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a medicament containing a Toll-like receptor agonist and LAG-3 protein, a mutant thereof, or a derivative thereof.
- cancer vaccine therapy is a method of inducing cancer by inducing a specific immune response against a cancer antigen in the body of the patient by directly administering the cancer antigen to the patient.
- cancer antigens administered to patients cancer antigen proteins themselves, cancer antigen-derived peptides, nucleic acids encoding them, dendritic cells presenting cancer antigens, and cancer cells themselves are used. .
- adjuvants are also administered together with cancer antigens.
- As adjuvants cytokines and Toll-like receptor (TLR) agonists that stimulate various immunocompetent cells are used.
- TLR agonist As the Toll-like receptor agonist (TLR agonist) used for the adjuvant, any agonist of TLR1 to TLR10 can be used (for example, Non-Patent Documents 1 and 2).
- TLR3 is one of the innate immune system molecules that recognizes virus-derived double-stranded RNA and promotes the production of type I interferons that exhibit strong antiviral activity. It is known that a double-stranded RNA analog Poly I: C (also called polyinosinic: polycytidylic acid) known as a TLR3 agonist is also used as an adjuvant for vaccines (for example, Patent Document 1). .
- TLR9 is one of the innate immune system molecules that recognizes and functions unmethylated CpG DNA derived from bacteria and viruses. It is known that CpG ODN (synthetic nucleic acid CpG oligodeoxynucleotide) which is a ligand of TLR9 also has an adjuvant effect for vaccines.
- CpG ODN synthetic nucleic acid CpG oligodeoxynucleotide
- LAG-3 is known to be used as an adjuvant for vaccines (for example, Patent Document 2).
- LAG-3 is a translation product of a lymphocyte activation gene (lymphocyte activation gene 3) and is also called CD223.
- LAG-3 binds to MHC class II molecules, negatively regulates the proliferation of activated T cells and maintains homeostasis of T cells, and plays an important role in the function of regulatory T cells (Treg) It is also known to be involved in the regulation of plasma cell dendritic cell homeostasis.
- OncoImmunology 1 5, 699-716; August 2012
- OncoImmunology 2 8, e25238; August 2013
- An object of the present invention is to provide a medicine containing a novel combination of adjuvants.
- the present inventors have found a novel combination as a drug useful for inducing cancer immunity. That is, the present invention is as follows. [1] A Toll-like receptor agonist, LAG-3 protein, a variant thereof, or a derivative thereof, Containing a medicament. [2] A Toll-like receptor agonist, The pharmaceutical agent according to [1], wherein the LAG-3 protein, a mutant thereof, or a derivative thereof is administered in combination. [3] The medicament according to [1] or [2], wherein the Toll-like receptor agonist is Toll-like receptor 3 agonist or Toll-like receptor 9 agonist.
- [6 ''] A Toll-like receptor agonist, LAG-3 protein, a variant thereof, or a derivative thereof, The medicament according to [6 ′], which is used in combination with a substance that induces a specific immune response against at least one cancer cell.
- [8] [7] The medicament according to [7], wherein the at least one cancer antigen-derived peptide is an HSP70-derived peptide or a GPC3-derived peptide.
- the medicament according to [9] comprising an HSP70-derived peptide having the amino acid sequence represented by SEQ ID NO: 7 or a GPC3-derived peptide having the amino acid sequence represented by SEQ ID NO: 16.
- HSP70-derived peptide, cancer antigen-derived peptide other than HSP70-derived peptide, Poly ICLC The medicament according to [12], comprising LAG-3 protein or a fusion protein of LAG-3 protein and IgG.
- GPC3-derived peptides and cancer antigen-derived peptides other than GPC3-derived peptides, Poly ICLC The medicament according to [13], comprising LAG-3 protein or a fusion protein of LAG-3 protein and IgG.
- HSP70-derived peptide, GPC3-derived peptide, Poly ICLC The medicament according to [14], comprising LAG-3 protein or a fusion protein of LAG-3 protein and IgG.
- a medicine containing a novel combination of adjuvants can be provided.
- FIG. 1 shows an outline of a test protocol comparing the effects of various adjuvants in a cancer vaccine using a cancer antigen-derived peptide.
- FIG. 2 shows the change in tumor size of one group using PBS as a control in the test of FIG.
- FIG. 3 shows the change in tumor size of the two groups using IFA as an adjuvant in the test of FIG.
- FIG. 4 shows the change in tumor size of the 3 groups using PT as an adjuvant in the test of FIG.
- FIG. 5 shows the change in tumor size of 4 groups using Poly I: C as an adjuvant in the test of FIG.
- FIG. 6 shows the change in tumor size of 5 groups using the combination of Poly I: C and CpG as adjuvant in the test of FIG.
- FIG. 1 shows an outline of a test protocol comparing the effects of various adjuvants in a cancer vaccine using a cancer antigen-derived peptide.
- FIG. 2 shows the change in tumor size of one group using PBS as a control in the test of
- FIG. 7 shows changes in tumor size of 6 groups using LAG-3Ig as an adjuvant in the test of FIG.
- FIG. 8 shows the change in tumor size of 7 groups using the combination of LAG-3Ig and PolyI: C as an adjuvant in the test of FIG.
- FIG. 9A shows a hematoxylin-eosin stained image of tumor tissue in the same test as in FIG.
- FIG. 9B shows fluorescent staining images of the nucleus and immune cells of the tumor tissue in the same test as in FIG.
- FIG. 10 shows that mice that were able to suppress the increase in tumor size by cancer vaccine (when LAG-3Ig and PolyPoI: C were used as adjuvants) in the same test as FIG. 1 were inoculated with tumor cells again at a later date.
- FIG. 11A lymph nodes were collected from mice vaccinated with a cancer vaccine in the same test as in FIG. 1, and immune cells separated from the lymph nodes were co-cultured with tumor cells previously inactivated by irradiation with radiation. Then, the result of having measured the proliferation ability of the immune cell is shown.
- FIG. 11B shows the results of measuring the amount of cytokine and the like in the cell supernatant after the same co-culture as in FIG. 11A.
- FIG. 12A shows that lymph nodes were collected from mice vaccinated with a cancer vaccine in the same test as in FIG.
- FIG. 12B shows that lymph nodes were collected from mice vaccinated with cancer vaccine in the same test as in FIG. 1, and cell surface marker molecules PD-1, BTLA, TIGIT, and LAG ⁇ in CD4 positive immune cells isolated from the lymph nodes were collected. The result of having measured the expression of 3 is shown.
- FIG. 13A shows the measurement results of immune cell proliferation ability.
- FIG. 13B shows the measurement result of IFN- ⁇ production.
- FIG. 14 shows the change in tumor size for one group using PBS as a control.
- FIG. 15 shows the change in tumor size of the two groups using Poly I: C as an adjuvant.
- FIG. 16 shows the change in tumor size of the 3 groups using the combination of LAG-3Ig and PolyI: C as adjuvant.
- FIG. 17 shows changes in tumor size of the 4 groups using only the combination of LAG-3Ig and PolyI: C without using the P1A peptide.
- FIG. 18 shows the change in tumor size of 5 groups using RIBOXXOL as an adjuvant.
- FIG. 19 shows changes in tumor size of 6 groups using a combination of LAG-3Ig and RIBOXXOL as an adjuvant.
- FIG. 20 shows the change in tumor size of 7 groups using a combination of LAG-3Ig and MPL as an adjuvant.
- FIG. 21 shows the change in tumor size of 8 groups using the combination of LAG-3Ig and Imiquimod as adjuvant.
- FIG. 22 shows the change in tumor size of 9 groups using the combination of LAG-3Ig and CpG as an adjuvant.
- FIG. 23 shows the change in tumor size for one group using IFA as an adjuvant.
- FIG. 24 shows the change in tumor size of the two groups using Poly I: C as an adjuvant.
- FIG. 25 shows the change in tumor size of the three groups using LAG-3Ig as an adjuvant.
- FIG. 26 shows the change in tumor size of 4 groups using the combination of LAG-3Ig and PolyI: C as adjuvant.
- FIG. 27A shows that an esophageal cancer patient was administered with a combination of HSP70-derived peptide, GPC3-derived peptide, Poly ICLC (product name “Hiltonol”) and LAG-3Ig (IMP321) 10 times, and then separated and cultured from patient blood. The amount of IFN- ⁇ production from immune cells is shown.
- FIG. 27B shows that a combination of HSP70-derived peptide, GPC3-derived peptide, Poly ICLC (product name “Hiltonol”) and LAG-3Ig (IMP321) was administered 10 times to a liver cancer patient, and then separated and cultured from patient blood. The amount of IFN- ⁇ production from immune cells is shown.
- FIG. 28A shows that a combination of HSP70-derived peptide, GPC3-derived peptide, Poly ICLC (product name “Hiltonol”) and LAG-3Ig (IMP321) was administered four times to a liver cancer patient, and then separated and cultured from patient blood. The amount of IFN- ⁇ production from immune cells is shown.
- FIG. 28B shows that a combination of HSP70-derived peptide, GPC3-derived peptide, Poly ICLC (product name “Hiltonol”) and LAG-3Ig (IMP321) was administered 8 times to rectal cancer patients, and then separated and cultured from patient blood. The amount of IFN- ⁇ production from immune cells is shown.
- 28C shows an esophageal cancer patient who was administered a combination of HSP70-derived peptide, GPC3-derived peptide, Poly ICLC (product name “Hiltonol”) and LAG-3Ig (IMP321) eight times, and then separated and cultured from patient blood. The amount of IFN- ⁇ production from immune cells is shown.
- the medicament according to the present invention includes a Toll-like receptor agonist (TLR agonist) and LAG-3 protein, a mutant thereof, or a derivative thereof.
- TLR agonist Toll-like receptor agonist
- LAG-3 protein a mutant thereof, or a derivative thereof.
- TLR agonist refers to a molecule that, when bound to any Toll-like receptor (TLR), stimulates the same as when a natural ligand binds to TLR.
- TLR agonists include Non-Patent Documents 1 and 2, Trends in Immunology, Vol. 30, No. 1, 23-32, Immunity 33, October 29, 2010, 492-503, World Journal of Vaccines, 2011, 1, 33. -78 and OncoImmunology 1: 6, 894-907; September 2012 are known TLR agonists, and these known TLR agonists can be used as TLR agonists in the present invention.
- TLR agonists include TLR1 agonists to TLR10 agonists.
- TLR3 agonists TLR4 agonists, TLR7 agonists, TLR8 agonists, TLR9 agonists, or TLR10 agonists can be used.
- the TLR agonist may be a TLR3 agonist or a TLR9 agonist.
- TLR1 agonist means a molecule that, when bound to TLR1, gives stimulation in the same manner as when a natural ligand is bound to TLR1.
- TLR1 recognizes lipoprotein and activates the innate immune system.
- TLR1 agonists include lipoprotein, triacylated lipopeptides, and Zymosan.
- TLR2 agonist means a molecule that, when bound to TLR2, provides stimulation in the same manner as when a natural ligand is bound to TLR2.
- TLR2 recognizes Acylated lipopeptides and activates the innate immune system.
- TLR2 agonist include SMP-105, Acylated lipopeptides, Amphotericin B, Atypical LPS, Byglican, Forins, Glyco (phospho) lipids, Lipoteichoic acid, Peptidoglycan, Phenol soluble modulin, and Zymosan.
- TLR3 agonist means a molecule that, when bound to TLR3, provides stimulation in the same manner as when a natural ligand is bound to TLR3.
- TLR3 recognizes virus-derived double-stranded RNA and activates the innate immune system.
- Poly I: C which is a synthetic double-stranded polynucleotide similar in structure to double-stranded RNA, is known, but is not limited thereto.
- Poly I: C may be a salt thereof, for example, a sodium salt.
- Poly ICLC can also be used as Poly I: C.
- RIBOXXOL can also be used as a TLR3 agonist.
- TLR3 agonist examples include Poly I: C, Poly ICLC (product name “Hiltonol”), RIBOXXOL, Ampligen, IPH-3102, cM362-139, and cM362-140.
- Poly I: C is preferably used.
- Poly I: C Poly ICLC (product name “Hiltonol”) stabilized with Poly-Lysine and Carboxymethylcellulose is used.
- TLR4 agonist means a molecule that, when bound to TLR4, provides stimulation in the same manner as when a natural ligand is bound to TLR4.
- TLR4 recognizes bacterial lipopolysaccharide (LPS) and activates the innate immune system.
- MPL is known as a TLR4 agonist, but is not limited thereto.
- MPL may be a salt thereof, for example, a sodium salt.
- the TLR4 agonist include MPL, MPLA, OM-174 (CRX-527), Picibanil (OK-432), ONO-4007, and the like.
- TLR5 agonist means a molecule that, when bound to TLR5, provides stimulation in the same manner as when a natural ligand is bound to TLR5.
- TLR5 recognizes bacterial flagellin and activates the innate immune system.
- flagellin derived from various bacteria or a recombinant protein of flagellin is known, but is not limited thereto. Examples of the TLR5 agonist include CBLB502.
- TLR6 agonist means a molecule that, when bound to TLR6, provides stimulation in the same manner as when a natural ligand is bound to TLR6. TLR6 recognizes lipoprotein and activates the innate immune system. Examples of TLR6 agonists include Diacylated lipopeptides, Lipoproteins, Lipoteichoic acid, and Zymosan.
- TLR7 agonist means a molecule that, when bound to TLR7, provides stimulation in the same manner as when a natural ligand is bound to TLR7.
- TLR8 agonist refers to a molecule that, when bound to TLR8, gives stimulation in the same manner as when a natural ligand is bound to TLR8.
- TLR7 and TLR8 recognize virus-derived single-stranded RNA and activate the innate immune system.
- Imiquimod is known as a TLR7 / 8 agonist, but is not limited thereto.
- Imiquimod may be a salt thereof, for example, a sodium salt.
- TLR7 / 8 agonists examples include Imiquimod (S-26308, R-837), Resimiquimod (R-848), 3M-052, 852A, VTX-1463, VTX-2337, AZD8848 (DSP-3025), ANA773, And TMX-101.
- TLR9 agonist means a molecule that, when bound to TLR9, provides stimulation in the same manner as when a natural ligand is bound to TLR9.
- TLR9 recognizes CpG DNA from bacteria and viruses and activates the innate immune system.
- CpG ODN is known as a TLR9 agonist, but is not limited thereto.
- CpG ODN CpG oligodeoxynucleotide
- TLR9 agonists examples include CpG, CpG-28, CpG-685 (GNKG168), CpG-1826, CpG-7909 (PF-3512676, Agatolimod, promune (registered trademark)), ODN1585, IMO-2125, IMO-2055 (EMD1201081), CpG ODN such as ISS1018, MGN-1703, MGN-1706, AVE0675, QAX-935, SAR-21609, SD-101, and DIMS0150.
- TLR10 agonist means a molecule that, when bound to TLR10, provides stimulation in the same manner as when a natural ligand is bound to TLR10.
- TLR10 recognizes acylated lipopeptide and activates the innate immune system.
- TLR10 agonists include acylated lipopeptides.
- LAG-3 protein, a variant thereof, or a derivative thereof means a LAG-3 protein, a functional variant thereof, or a functional derivative thereof.
- the LAG-3 protein used in the present invention may be derived from any animal.
- the LAG-3 protein can be a protein derived from the same animal as the subject to which the medicament according to the present invention is administered. Accordingly, human LAG-3 can be used as long as the medicament according to the present invention is administered to humans.
- LAG-3 protein is a protein having the amino acid sequence shown in NCBI Accession No. P18627.5 in the case of humans.
- a functional variant of LAG-3 protein is (i) a variant of LAG-3 consisting of an amino acid sequence in which one or several amino acids are added, substituted, or deleted in the amino acid sequence of LAG-3. And having the function of the LAG-3 protein necessary for exerting the effects of the present invention, (ii) LAG-3 amino acid sequence and at least 80% or more, 85% or more, 90% or more, 95 % Or more, 98% or more, 99% or more of LAG-3 variant consisting of amino acid sequence having the function of LAG-3 necessary to exert the effect of the present invention, (iii) a LAG-3 protein, a mutant of the above (i), or a partial polypeptide of the mutant of (ii), which has the function of the LAG-3 protein necessary for exerting the effects of the present invention.
- “one or several” means one, two, three, four, five, six, seven, eight, nine, or ten.
- amino acid is used in its broadest sense and includes artificial amino acid variants and derivatives in addition to natural amino acids.
- amino acids are natural proteinaceous L-amino acids; D-amino acids; chemically modified amino acids such as amino acid variants and derivatives; natural non-protein amino acids such as norleucine, ⁇ -alanine, ornithine; and amino acid characteristics And chemically synthesized compounds having properties known in the art.
- non-natural amino acids include ⁇ -methyl amino acids (such as ⁇ -methylalanine), D-amino acids, histidine-like amino acids (such as ⁇ -hydroxy-histidine, homohistidine, ⁇ -fluoromethyl-histidine and ⁇ -methyl-histidine) And amino acids having an extra methylene in the side chain (“homo” amino acids) and amino acids in which the carboxylic acid functional amino acid in the side chain is substituted with a sulfonic acid group (such as cysteic acid).
- ⁇ -methyl amino acids such as ⁇ -methylalanine
- D-amino acids such as ⁇ -methylalanine
- histidine-like amino acids such as ⁇ -hydroxy-histidine, homohistidine, ⁇ -fluoromethyl-histidine and ⁇ -methyl-histidine
- amino acids having an extra methylene in the side chain (“homo” amino acids) and amino acids in which the carboxylic acid functional amino acid in the side chain is substituted with
- Examples of functional derivatives of LAG-3 protein include fusion proteins of all or part of LAG-3 protein with other proteins or polypeptides, proteins with sugar chains and lipids added to LAG-3 protein, etc. It is done.
- An example of a functional derivative of LAG-3 protein is a fusion protein of LAG-3 and IgG (LAG-3Ig).
- Examples of functional derivatives of LAG-3 protein include those described in Journal of Translational Medicine 2014, 12:97.
- As a functional derivative of LAG-3 protein specifically, IMP321 (LAG-3Ig), which is a fusion protein of LAG-3 and IgG, can be preferably used.
- the medicament according to the present invention includes a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof, and as the TLR agonist, a TLR3 agonist or a TLR9 agonist can be preferably used. It can be used more suitably.
- human LAG-3 or LAG-3Ig can be preferably used as the LAG-3 protein, a mutant thereof, or a derivative thereof.
- a combination of a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof includes a TLR3 agonist or a TLR9 agonist and a combination of a LAG-3 protein, a variant, or a derivative thereof, or a TLR agonist, and a LAG.
- a TLR3 agonist or TLR9 agonist and a LAG-3 protein or LAG-3 protein derivative more preferably a combination of a TLR3 agonist or TLR9 agonist and a LAG-3 protein or LAG-3 protein derivative, a TLR3 agonist and LAG -3 protein or a combination of derivatives of LAG-3 protein is more preferable, and a combination of a TLR3 agonist and a derivative of LAG-3 protein is still more preferable.
- Poly I: C or a salt thereof can be used as a TLR3 agonist
- Poly ICLC may be used as Poly I: C. .
- TLR3 agonist Poly I: C, Poly ICLC (product name “Hiltonol”), RIBOXXOL, Ampligen, IPH-3102, cM362-139, cM362-140, and the like may be used.
- Poly ICLC product name “Hiltonol”
- CpG ODN or a salt thereof may be used as a TLR9 agonist, or a sodium salt of CpG ODN may be used.
- TLR9 agonists include CpG, CpG-28, CpG-685 (GNKG168), CpG-1826, CpG-7909 (PF-3512676, Agatolimod, promune (registered trademark)), ODN1585, IMO-2125, IMO-2055 (EMD1201081), ISS1018, MGN-1703, MGN-1706, AVE0675, QAX-935, SAR-21609, SD-101, DIMS0150, etc. may be used.
- the LAG-3 protein, a variant, or a derivative thereof includes the above-described LAG-3 protein, a functional variant thereof, or A functional derivative thereof can be used, but a functional derivative of LAG-3 protein or a fusion protein of human LAG-3 or LAG-3 and IgG (LAG-3Ig) may be used.
- the medicament according to the present invention preferably includes a substance that induces a specific immune response against cancer cells, in addition to a TLR agonist and a LAG-3 protein, a mutant thereof, or a derivative thereof.
- a medicament further containing a substance that induces a specific immune response against cancer cells it can be a combination of the above-described TLR agonist and LAG-3 protein, a variant thereof, or a derivative thereof.
- the medicament according to the present invention preferably includes a TLR3 agonist or a TLR9 agonist, a LAG-3 protein or a derivative of LAG-3 protein, and a substance that induces a specific immune response against cancer cells. More preferably, the medicament according to the present invention comprises a TLR3 agonist, a LAG-3 protein or a derivative of LAG-3 protein, and a substance that induces a specific immune response against cancer cells.
- the medicament according to the present invention comprises a TLR3 agonist, a derivative of LAG-3 protein, and a substance that induces a specific immune response against cancer cells.
- the medicament according to the present invention further includes a substance that induces a specific immune response against cancer cells
- the substance that induces a specific immune response against cancer cells includes cancer antigen protein, cancer antigen-derived Peptides, nucleic acids encoding them, cancer antigen-presenting cells, and tumor cells may be used, and cancer antigen-derived peptides are preferably used.
- the medicament according to the present invention is used for cancer immunotherapy, it is preferable that (1) antigen presentation in the nearest dendritic cell, (2) nearest place by subcutaneous administration or intradermal administration. Activation of T cell priming in lymph nodes, (3) It is considered that the induced antigen peptide-specific CTL recognizes the tumor at the tumor site and causes injury.
- a TLR3 agonist is used as a TLR agonist in the medicament according to the present invention will be described as an example.
- a substance that induces a specific immune response against cancer cells administered simultaneously with the TLR3 agonist is presented as an antigen, and T cell priming is performed. Is promoted.
- LAG-3Ig when used as an example of LAG-3 protein, a mutant thereof, or a derivative thereof, antigen presentation to a substance that induces a specific immune response against cancer cells will be described. It is expected to suppress fatigue of CTLs in the tumor site by blocking the suppression signal for active CTLs by tumors or macrophages expressing MHC Class II molecules.
- TLR3 agonist and LAG-3Ig is thought to enhance tumor damage independently of substances that induce a specific immune response against cancer cells administered simultaneously.
- a “substance that induces a specific immune response against cancer cells” is a substance that can induce an immune response that destroys cancer cells in vivo or induces apoptosis of cancer cells. If it is, it will not specifically limit, For example, cancer antigen protein, cancer antigen origin peptide, the nucleic acid which codes them, cancer antigen presentation cell, tumor cell itself is mentioned.
- cancer antigen protein is a protein that is specifically expressed in cancer cells that the immune system recognizes and attacks as a foreign substance. It may be expressed in cancer cells of all cancer types or expressed in cancer cells of a specific cancer type. As the cancer antigen protein, a protein having strong immunogenicity and not expressed at all in normal cells is preferable. Although it does not specifically limit as a cancer antigen protein, What is described in Clin Cancer Res 2009; 15 (17) 5323 is mentioned.
- the “cancer antigen-derived peptide” has a peptide having a partial amino acid sequence of a cancer antigen protein, or a sequence including addition, substitution, or deletion of 1 or 2 amino acids in the amino acid sequence.
- the cancer antigen-derived peptide may be composed of 8 or more and 11 or less amino acid residues. When such a peptide is administered subcutaneously to a patient, it is taken up by antigen-presenting cells such as dendritic cells and macrophages and presented together with HLA molecules on the cell surface.
- Cytotoxic T cell (CTL) progenitor cells that are reactive to the presented peptides are clonally proliferated, and the proliferated and differentiated mature CTL migrates to the cancer tissue via lymph flow. Mature CTL attacks peptide-expressing cancer cells having the same sequence as the administered peptide and induces apoptosis.
- the peptide derived from HSP70 as the cancer antigen-derived peptide is not particularly limited, and examples thereof include the peptides described in International Publication No. 2016/056596, specifically, SEQ ID NOs: 1 to 15 Examples thereof include peptides comprising 8 or more consecutive amino acid residues in the amino acid sequence represented by any one and consisting of 11 or less amino acid residues.
- an HSP70-derived peptide when used, it is not particularly limited, but an HSP70-derived peptide having an amino acid sequence represented by any of SEQ ID NOs: 1 to 15 can be preferably used.
- An HSP70-derived peptide having the amino acid sequence represented by SEQ ID NO: 7 is more preferably used.
- the GPC3-derived peptide as the cancer antigen-derived peptide is not particularly limited, and examples thereof include the peptides described in International Publication No. 2016/143816. Specifically, the peptides of SEQ ID NOs: 16 to 26 are exemplified. Examples thereof include peptides comprising 8 or more consecutive amino acid residues in the amino acid sequence represented by any one and consisting of 11 or less amino acid residues.
- a GPC3-derived peptide when used, it is not particularly limited, but a GPC3-derived peptide having an amino acid sequence represented by any of SEQ ID NOs: 16 to 26 can be preferably used, A GPC3-derived peptide having the amino acid sequence represented by SEQ ID NO: 16 is more preferably used.
- the MUC1-derived peptide as the cancer antigen-derived peptide is not particularly limited, and examples thereof include the peptides described in International Publication No. 2016/143814. Specifically, the peptides of SEQ ID NOs: 27 to 39 are exemplified.
- Examples thereof include peptides comprising 8 or more consecutive amino acid residues in the amino acid sequence represented by any one and consisting of 11 or less amino acid residues.
- These antigen-derived peptides are disclosed as examples, and “substances that induce a specific immune response against cancer cells” used in the medicament according to the present invention are limited to these antigen-derived peptides. is not.
- nucleic acid is not particularly limited as long as it is a nucleic acid encoding cancer antigen protein or cancer antigen-derived peptide, and includes RNA, DNA, PNA, LNA, or a chimera of two or more thereof. . These nucleic acids can be inserted into a vector or the like and administered to a patient according to a known method, and express a cancer antigen protein or a cancer antigen-derived peptide in vivo.
- the “cancer antigen-presenting cell” means an antigen-presenting cell that is present on the surface of the HLA molecule bound with a cancer antigen-derived peptide.
- Dendritic cells and macrophages can be used as antigen-presenting cells. Dendritic cells are particularly highly capable of inducing CTL.
- the dendritic cells presenting the antigen are, for example, isolated mononuclear cells from the patient's own peripheral blood and differentiated into immature dendritic cells, and then added cancer antigen protein or cancer antigen-derived peptide to the medium. And further differentiated into mature dendritic cells.
- the medicament according to the present invention can contain at least one kind of “substance that induces a specific immune response against cancer cells”, but may contain two or more kinds.
- the medicament according to the present invention may contain a cancer antigen-derived peptide derived from one type of cancer antigen protein as “a substance that induces a specific immune response against cancer cells”, and two or more types of peptides may be used.
- a cancer antigen-derived peptide derived from a cancer antigen protein may be included.
- the medicament according to the present invention preferably contains at least one cancer antigen-derived peptide.
- the at least one cancer antigen-derived peptide is not particularly limited, and one cancer antigen-derived peptide may be used, or two or more cancer antigen-derived peptides may be used.
- cancer antigen proteins in cancer antigen-derived peptides derived from cancer antigen proteins include proteins selected from the cancer antigen proteins listed for “cancer antigen proteins”. As two or more types of cancer antigen-derived peptides, two or more types of cancer antigen-derived peptides derived from different cancer antigen proteins may be used. An antigen-derived peptide may be used. Examples of the two or more different cancer antigen proteins include two or more different proteins selected from the cancer antigen proteins listed for “cancer antigen protein”.
- HSP70, GPC3, MUC1, or gp100-derived peptides are preferably used as cancer antigen-derived peptides, and HSP70-derived peptides or GPC3-derived peptides are more preferably used.
- the medicament according to the present invention contains one kind of cancer antigen-derived peptide, it is preferable to use an HSP70-derived peptide or a GPC3-derived peptide.
- the medicament according to the present invention contains two or more types of cancer antigen-derived peptides, it is preferable to use an HSP70, GPC3, MUC1, or gp100-derived peptide as one of the two or more types.
- the two types of cancer antigen-derived peptides include HSP70-derived peptides and combinations of cancer antigen-derived peptides other than HSP70-derived peptides, GPC3-derived peptides and combinations of cancer antigen-derived peptides other than GPC3-derived peptides, HSP70 A combination of a derived peptide and a GPC3-derived peptide is preferably used.
- HSP70 and GPC3 are selected as proteins selected from cancer antigen proteins listed for "cancer antigen proteins", respectively.
- Examples include cancer antigen-derived peptides derived from excluded antigen proteins.
- a combination of two types of HSP70-derived peptide and GPC3-derived peptide is preferable.
- two or more kinds of “substances that induce a specific immune response against cancer cells” include cancer antigen proteins, cancer antigen-derived peptides, nucleic acids encoding them, cancer antigen-presenting cells, and tumor cells. Two or more types may be selected, and a case where a substance that induces a specific immune response against two types of cancer cells is exemplified will be described.
- One kind selected may be included.
- the medicament according to the present invention can be used for cancer vaccine therapy.
- the TLR agonist and the LAG-3 protein, a variant thereof, or a derivative thereof function as an adjuvant and enhance the induction of an immune response by “a substance that induces a specific immune response against cancer cells”.
- a substance that induces a specific immune response against cancer cells As shown in the examples described later, when a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof are used in combination, even when used at a low dose, the effect cannot be obtained when used alone. High antitumor effect can be obtained.
- adjuvant means a group of molecules that enhances the induction of an immune response when administered together with a substance that induces the immune response.
- Cancer vaccine therapy can be used for cancer prevention or treatment.
- the prevention or treatment of cancer includes reduction in tumor size, delay or stop of increase, inhibition of cancer metastasis (delay or stop), inhibition of cancer cell growth (delay or stop), It means causing at least one of inhibition (delay or cessation) of cancer recurrence and alleviation of one or more symptoms associated with cancer.
- cancer is used herein in its broadest sense and includes astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, schwannoma, nerve Fibrosarcoma, neuroblastoma, pituitary tumor (eg, pituitary adenoma), medulloblastoma, melanoma, brain tumor, prostate cancer, head and neck cancer, esophageal cancer, renal cancer, renal cell cancer, pancreatic cancer, Breast cancer, lung cancer, colon cancer, colon cancer, stomach cancer, skin cancer, ovarian cancer, bladder cancer, fibrosarcoma, squamous cell carcinoma, neuroectodermal, thyroid tumor, lymphoma, leukemia, multiple myeloma, hepatocellular carcinoma, mesothelial Examples include, but are not limited to, epidermoid carcinoma and the like.
- the present invention also includes an adjuvant for cancer vaccine therapy comprising a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof.
- a TLR agonist is an adjuvant for administration in combination with a LAG-3 protein, variant thereof, or a derivative thereof, and a LAG-3 protein, variant, or derivative thereof is an adjuvant for administration in combination with a TLR agonist obtain.
- Such an adjuvant may be administered to a patient together with various “substances that induce a specific immune response against cancer cells”. As used herein, the meaning of “together” does not mean that they are administered at the same time, and the TLR agonist and the LAG-3 protein, a variant thereof, or a derivative thereof are inside or outside the patient.
- a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof are administered to a patient so that they can function as an adjuvant in cancer vaccine therapy.
- a LAG-3 protein, a variant thereof, or a derivative thereof may be a drug containing a TLR agonist, or a LAG-3 protein for administration in combination with a TLR agonist, its It may be a pharmaceutical containing a mutant or a derivative thereof.
- a medicament containing such a TLR agonist is used as a LAG-3 protein, a variant thereof, or a derivative thereof and an adjuvant, and induces a specific immune response against cancer cells, preferably a peptide derived from a cancer antigen. , Can enhance the induction of immune response.
- a substance containing a LAG-3 protein, a variant thereof, or a derivative thereof for administration in combination with a substance that induces a specific immune response against cancer cells and a TLR agonist A medicament containing such LAG-3 protein, a variant thereof, or a derivative thereof is used as a TLR agonist and an adjuvant to induce a specific immune response against cancer cells, preferably against a cancer antigen-derived peptide. Induction of response may be enhanced.
- a pharmaceutical comprising the TLR agonist according to the present invention and a LAG-3 protein, a variant thereof, or a derivative thereof, and a TLR agonist and the LAG-3 protein, a variant thereof, or a derivative thereof are used as an active ingredient of the pharmaceutical.
- You can also A pharmaceutical comprising a TLR agonist according to the present invention and a LAG-3 protein, a variant thereof, or a derivative thereof as an active ingredient is used as an anticancer agent exhibiting a high antitumor effect, as shown in Examples described later. It can also be done.
- anticancer agent means an agent that can be used for the prevention or treatment of cancer.
- a drug that is an anticancer agent may contain a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof as active ingredients, and a substance that induces a specific immune response against cancer cells. Further, it may be included. Further, in the present invention, the medicament that is an anticancer agent contains, as an active ingredient, a substance that induces a specific immune response against cancer cells, preferably a peptide derived from a cancer antigen, and as an adjuvant, a TLR agonist and , LAG-3 protein, a variant thereof, or a derivative thereof.
- Each component of the pharmaceutical agent according to the present invention can be dissolved in a water-soluble solvent, formulated into a pharmaceutically acceptable salt form, and administered to a patient.
- Such pharmaceutically acceptable salt forms are buffered at physiological pH in the form of physiologically acceptable water-soluble salts such as sodium, potassium, magnesium, and calcium salts. A form is mentioned.
- a water-insoluble solvent can also be used. Examples of such a water-insoluble solvent include alcohols such as ethanol and propylene glycol.
- the medicament according to the present invention can be used as a pharmaceutical composition, and can be administered orally or parenterally in any aspect of the pharmaceutical composition, and its dosage form is not particularly limited.
- the dosage form of the pharmaceutical composition for example, liquid (for example, injection), dispersion, suspension, tablet, pill, powder, suppository, powder, fine granule, granule, capsule, syrup , Nasal drops and ear drops.
- parenteral administration for example, intraperitoneal administration, subcutaneous administration, intradermal administration, intramuscular administration, intravenous administration, or intranasal administration can be used.
- the pharmaceutical preparation according to the present invention can be prepared according to a known method.
- pharmaceutically acceptable carriers and additives excipients, binders, dispersants, disintegrants, lubricants, solubilizers, solubilizers, colorants, flavoring agents
- Stabilizers emulsifiers, suspending agents, absorption promoters, surfactants, pH adjusting agents, preservatives, antioxidants, and the like.
- carriers and additives include pharmaceutically acceptable organic solvents such as water, saline, phosphate buffer, dextrose, glycerol, ethanol, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, Sodium polyacrylate, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, glutamic acid, aspartic acid, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycol Glycerin, glycerin, propylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, Serum albumin, mannitol, sorbitol, lactose, glucose, corn starch, microcrystalline cellulose, surfactant, sodium bisulfite, sodium bisulfate, sodium thios
- surfactants such as polyoxyethylene lauryl ethers, sodium lauryl sulfate, and saponins are used as absorption accelerators for improving absorption of poorly absorbable drugs that are difficult to be absorbed through mucosal membrane
- Bile salts such as glycocholic acid, deoxycholic acid and taurocholic acid
- chelating agents such as EDTA and salicylic acids
- fatty acids such as caproic acid, capric acid, lauric acid, oleic acid, linoleic acid and mixed micelles
- enamine derivatives N-acyl collagen peptides, N-acyl amino acids, cyclodextrins, chitosans, nitric oxide donors, and the like can be used.
- the medicament according to the present invention contains a peptide
- it may be encapsulated or adsorbed in polylactic acid / glycolic acid (PLGA) microcapsules or porous hydroxyapatite fine particles to give sustained release, and pulse-release iontophoresis It may be percutaneously absorbed using a patch system.
- PLGA polylactic acid / glycolic acid
- the medicament according to the present invention may contain, as one preparation, a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof, and each of them as a separate preparation, that is, a preparation containing a TLR agonist. And a combination with a preparation containing the LAG-3 protein, a variant thereof, or a derivative thereof. Further, the medicament according to the present invention includes, as one preparation, a substance that induces a specific immune response against cancer cells, a TLR agonist, and a LAG-3 protein, a mutant thereof, or a derivative thereof.
- each contains a preparation that contains a substance that induces a specific immune response against cancer cells, a preparation that contains a TLR agonist, and a LAG-3 protein, a variant thereof, or a derivative thereof. It may be a combination with a preparation.
- a combination of preparations may be used, and a combination of three kinds of components may be used, and a combination of a preparation containing any two kinds of ingredients and a preparation containing any two kinds of ingredients may be used.
- the medicament according to the present invention may be a kit.
- the kit may comprise a TLR agonist and a LAG-3 protein, a variant or derivative thereof, a substance that induces a specific immune response against cancer cells, and a TLR.
- a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof may be included.
- an additional adjuvant may be included.
- additional adjuvants include precipitating adjuvants such as aluminum hydroxide, sodium hydroxide, aluminum phosphate, calcium phosphate, alum, and carboxyvinyl polymer, as well as Freund's complete adjuvant, Freund's incomplete adjuvant, liquid paraffin, Oily adjuvants such as lanolin, Montanide ISA763AV, and Montanide ISA51 can be mentioned.
- the medicament according to the present invention may be used in combination with other anticancer agents, or may be combined with radiation therapy or surgical treatment.
- Other anticancer agents include adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexate, 5-fluorouracil, aclacinomycin, nitrogen mustard, cyclophosphamide, bleomycin, daunorubicin, doxorubicin, vincristine, vinblastine , Low molecular weight compounds such as vindesine, tamoxifen, and dexamethasone, and cytokines that activate immunocompetent cells (eg, human interleukin 2, human granulocyte macrophage colony stimulating factor, human macrophage colony stimulating factor, and human interleukin 12) And the like.
- immunocompetent cells eg, human interleukin 2, human granulocyte macrophage colony stimulating factor, human macrophage colony stimulating factor, and
- the present invention also includes a method for treating cancer by administering a therapeutically effective amount of the medicament according to the present invention.
- the therapeutically effective amount can be appropriately determined by those skilled in the art according to the patient's symptoms, age, sex, weight, sensitivity difference, administration method, administration interval, type of preparation, and the like.
- a patient's disease can be treated or prevented by administering a TLR agonist, a LAG-3 protein, a mutant thereof, or a derivative thereof, and a patient in need thereof.
- the present invention also includes a TLR agonist, a LAG-3 protein, a mutant thereof, or a derivative thereof, and a method for inducing a specific immune response against cancer cells that is administered to a patient in need thereof. provide.
- a substance that induces a specific immune response against cancer cells preferably a peptide derived from a cancer antigen Further administration may be performed.
- a substance that induces a specific immune response against cancer cells preferably a cancer antigen-derived peptide, can be exerted more potently.
- the medicament according to the present invention is preferably administered in combination.
- Administration of the medicament according to the present invention means that a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof may be administered to a patient, each in any combination, at the same time, It may be administered at another time.
- the medicament according to the present invention contains a substance that induces a specific immune response against cancer cells, a substance that induces a specific immune response against cancer cells, a TLR agonist, and a LAG-3 protein , A mutant thereof, or a derivative thereof may be administered in any combination, at the same time, or at another time. When administered at the same time, it may be administered simultaneously as a single preparation.
- a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof are mixed to prepare a dosage preparation for simultaneous administration. May be.
- the LAG-3 protein, a variant, or a derivative thereof may be administered after administering the TLR agonist, or after the LAG-3 protein, a variant, or a derivative thereof is administered.
- a TLR agonist may be administered.
- the medicament according to the present invention contains a substance that induces a specific immune response against cancer cells
- it when administered simultaneously, it may be administered simultaneously as one preparation, and at the time of administration, the cancer cells
- a substance that induces a specific immune response against a TLR agonist, a LAG-3 protein, a mutant thereof, or a derivative thereof may be mixed to prepare a dosage formulation and administered simultaneously.
- the TLR agonist and the LAG-3 protein, a variant, or a derivative thereof are simultaneously or separately.
- a TLR agonist and a LAG-3 protein, a variant thereof, or a derivative thereof may be administered simultaneously or separately, followed by administration of a substance that induces a specific immune response against cancer cells.
- a substance that induces a specific immune response against cancer cells is administered,
- the other of LAG-3 protein, a variant thereof, or a derivative thereof may be administered.
- it may be administered based on the administration interval of each component, that is, based on the respective administration regimen, according to the characteristics of each component.
- Cancer Vaccine According to the protocol shown in FIG. 1, the effects of various adjuvants in a cancer vaccine using a cancer antigen-derived peptide were compared.
- P815 cells (mouse mastocytoma derived from DBA / 2 mice) were transplanted into DBA / 2 mice.
- a cancer antigen-derived peptide a peptide (hereinafter referred to as “P1A peptide”) that consists of a partial sequence of the P1A protein, which is a tumor antigen of P815 tumor, and is known to be presented in an MHC H-2Ld-restricted manner.
- the amino acid sequence of the P1A peptide is LPYLGWLVF (SEQ ID NO: 40).
- P1A CTL T cells expressing a T cell receptor recognizing P1A peptide were used.
- the spleen was collected from the P1A-CTL transgenic mice owned by the present inventor, and the positive rate was confirmed by TCR V ⁇ 8.3 (the TCR marker into which the gene was introduced). Was determined and administered.
- the following substances were used as adjuvants.
- Bordetella pertussis (PT) BioFarma, Bandung, Indonesia) Poly I: C (TLR3 agonist) (Invivogen, SanDiego, USA) CpG (TLR9 agonist) (Invivogen, SanDiego, USA) IFA (Incomplete Freund's Adjuvant) (Seppic, Paris, France) LAG-3Ig (Adipogen, SanDiego, USA)
- mice were inoculated subcutaneously with 5 ⁇ 10 5 cells of P815 tumor cells per mouse, and this day was designated as Day 0.
- 2.5 ⁇ 10 5 cells of P1A CTL per mouse were injected intravenously.
- 50 ⁇ g of P1A peptide per mouse and an adjuvant mixed in PBS were injected subcutaneously.
- the mice were divided into 9 groups of 5 mice, and the following adjuvants were used for each group.
- Group 1 PBS (control)
- Group 2 IFA (50 ⁇ L / mouse) 3 groups: PT (1 ⁇ 10 8 / mouse) 4 groups: Poly I: C (50 ⁇ g / mouse) 5 groups: Poly I: C (50 ⁇ g / mouse) + CpG (10 ⁇ g / mouse)
- Group 6 LAG-3Ig (1 ⁇ g / mouse)
- Group 7 LAG-3Ig (1 ⁇ g / mouse) + Poly I: C (50 ⁇ g / mouse)
- mice The changes in tumor size (mm 3 ) for all mice after Day 7 are shown in FIGS. In groups 1-6, the tumor size gradually increased, and many mice died along the way. 0 mice in groups 2, 3 and 6 survived until Day 70, 1 in groups 1 and 4 and 3 in group 5, all 5 in group 7 The mice did not increase in tumor size and survived until Day 115.
- mice were inoculated subcutaneously with 5 ⁇ 10 5 P815 tumor cells per mouse to form cancer model mice.
- 2.5 ⁇ 10 5 cells of P1A CTL per mouse were injected intravenously.
- 50 ⁇ g of P1A peptide per mouse and an adjuvant mixed in PBS were injected subcutaneously. The following adjuvants were used for each mouse.
- Group 1 IFA (50 ⁇ L / mouse)
- Group 2 Poly I: C (50 ⁇ g / mouse)
- Group 3 LAG-3Ig (1 ⁇ g / mouse)
- Group 4 LAG-3Ig (1 ⁇ g / mouse) + Poly I: C (50 ⁇ g / mouse)
- tumor tissue was collected on Day 21, and a preparation of a tumor tissue section was prepared.
- a tissue image was observed by staining with hematoxylin and eosin, and fluorescence staining of cell nuclei and immune cells (CD4 cells and CD8 cells) was performed.
- the following reagents were used for fluorescent tissue staining.
- CD4 cell primary antibody Rat Anti-Mouse CD4 Purified IgG2b. Clone: GK1.5 (eBioscience) CD4 cell secondary antibody: Mouse monoclonal (2B 10A8) Anti-Rat IgG2b heavy chain (Alexa FluorR 647), (abcam) CD8 cell primary antibody: Rat Anti-Mouse CD8 ⁇ Purified IgG2a. Clone: 53-6.7 (eBioscience) CD8 cell secondary antibody: Mouse monoclonal (2A 8F4) Anti-Rat IgG2a heavy chain (Alexa FluorR 488) (abcam)
- FIG. 9A shows a hematoxylin / eosin stained image
- FIG. 9B shows fluorescent stained images of cell nuclei and immune cells.
- mice 10 right shows the change in the average tumor size (mm 3 ) of the mice after inoculation with P815 cells.
- ⁇ is a DBA / 2 mouse judged to have rejected the tumor
- ⁇ is a naive DBA / 2 mouse.
- Naive DBA / 2 mice showed an increase in tumor size when inoculated with either P815 cells or L1210 cells.
- mice judged to have rejected tumor growth caused by P815 cells although tumor size increased with inoculation with another tumor cell, L1210 cells, an increase in tumor size with P815 cell inoculation was observed.
- Group 1 IFA (50 ⁇ L / mouse)
- Group 2 Poly I: C (50 ⁇ g / mouse)
- Group 3 LAG-3Ig (1 ⁇ g / mouse)
- Group 4 LAG-3Ig (1 ⁇ g / mouse) + Poly I: C (50 ⁇ g / mouse)
- lymph nodes close to the tumor site were collected from lymph nodes in the axilla or inguinal region, and 1.5 ⁇ 10 5 separated immune cells and 4 ⁇ 10 4 P815 cells irradiated with 100 Gy were co-cultured for 3 days.
- the immune cell proliferation ability was measured by adding 3 H-thymidine; 37 KBq / well to the culture supernatant and measuring the radioactivity of 3 H-thymidine incorporated into the cells after 4 hours.
- the amount of cytokine in the cell supernatant was measured using Bio-Plex Pro mouse cytokine 23-Plex Immunoassay kit (BIO-RAD).
- FIG. 11A shows the measurement results of immune cell proliferation ability
- FIG. 11B shows the measurement results of cytokines and the like.
- LAG-3Ig and poly I: C were combined as an adjuvant, an increase in immune cell proliferation ability was observed.
- production of IFN- ⁇ , GM-CSF, IL-4, IL-5, IL-17A is increased I understood.
- Group 1 IFA (50 ⁇ L / mouse)
- Group 2 Poly I: C (50 ⁇ g / mouse)
- Group 3 LAG-3Ig (1 ⁇ g / mouse)
- Group 4 LAG-3Ig (1 ⁇ g / mouse) + Poly I: C (50 ⁇ g / mouse)
- lymph nodes near the tumor site are collected from lymph nodes in the axilla or inguinal region, and CD8 and V ⁇ 8.3 expression positive cell group (killer T cell) or CD4 and V ⁇ 8.3 expression positive cell group (Helper T cells) were collected.
- the expression levels of PD-1, BTLA, TIGIT, and LAG-3 which are cell surface marker molecules of cells (CD4 cells and CD8 cells), were measured.
- PD-1 Anti-Mouse CD279 (PD-1) PE.
- BTLA Anti-Mouse CD272 (BTLA) PE.
- TIGIT PE anti-mouse TIGIT (Vstm3) Antibody.
- LAG-3 Anti-Mouse CD223 (Lag-3) PE.
- the results for CD8 cells are shown in FIG. 12A, and the results for CD4 cells are shown in FIG. 12B.
- both CD4 positive cells and CD8 positive cells showed a significant decrease in the expression level of PD-1, TIGIT, and LAG-3, but BTLA There was little decrease in the expression level.
- Group 1 IFA (50 ⁇ L / mouse)
- Group 2 Poly I: C (50 ⁇ g / mouse)
- Group 3 LAG-3Ig (1 ⁇ g / mouse)
- Group 4 LAG-3Ig (1 ⁇ g / mouse) + Poly I: C (50 ⁇ g / mouse)
- lymph nodes near the tumor site or both lymph nodes
- the cells were cultured in the presence of 2.5 or 0 ⁇ g / mL gp100 peptide.
- Immune cell growth capacity is determined by adding 3 H-thymidine; 37 KBq / well to the culture supernatant and measuring the radioactivity of 3 H-thymidine incorporated into the cells during the last 10 hours of the 3-day culture period was measured.
- the amount of IFN- ⁇ produced in the cell supernatant cultured for 3 days in the presence of 10 ⁇ g / mL gp100 peptide was measured using Bio-Plex Pro mouse cytokine 23-Plex Immunoassay kit (BIO-RAD).
- the measurement result of the immune cell proliferation ability is shown in FIG. 13A, and the measurement result of the IFN- ⁇ production amount is shown in FIG. 13B.
- FIG. 13A The measurement result of the immune cell proliferation ability is shown in FIG. 13A
- the measurement result of the IFN- ⁇ production amount is shown in FIG. 13B.
- ⁇ shows the results of 1 group
- ⁇ shows the 2 groups
- ⁇ shows the 3 groups
- ⁇ shows the results of the 4 groups.
- Group 1 P1A peptide only (control)
- Group 2 Poly I: C (50 ⁇ g / mouse) 3 groups: Poly I: C (50 ⁇ g / mouse) + LAG-3Ig (1 ⁇ g / mouse)
- Group 4 No P1A peptide, Poly I: C (50 ⁇ g / mouse) + LAG-3Ig (1 ⁇ g / mouse) only
- Group 5 RIBOXXOL (100 ⁇ g / mouse) 6 groups: RIBOXXOL (100 ⁇ g / mouse) + LAG-3Ig (1 ⁇ g / mouse) 7 groups: MPL (10 ⁇ g / mouse) + LAG-3Ig (1 ⁇ g / mouse) 8 groups: Imiquimod (50 ⁇ g / mouse) + LAG-3Ig (1 ⁇ g / mouse) 9 groups: CpG (10 ⁇ g / mouse) + LAG-3Ig (1 ⁇ g / mouse) Changes in tumor size (mm 3 ) for all mice after Day 7 are shown in FIGS.
- Group 1 IFA (50 ⁇ L / mouse)
- Group 2 Poly I: C (50 ⁇ g / mouse)
- Group 3 LAG-3Ig (1 ⁇ g / mouse)
- Group 4 LAG-3Ig (1 ⁇ g / mouse) + Poly I: C (50 ⁇ g / mouse) Changes in tumor size (mm 3 ) for all mice after Day 5 are shown in FIGS. Five mice in each group died on Day 31 in Group 1, Day 35 in Group 2, Day 37 in Group 3, and Day 37, while all mice died on Day 57 in Group 4. Compared to group 1, there was no significant effect of extending survival in groups 2 and 3, but in group 4, a significant increase in survival was confirmed for all groups 1, 2, and 3. It was.
- HSP70 peptide YGAAVQAAI: SEQ ID NO: 7
- 2 mg GPC3 peptide MVNELFDSL: SEQ ID NO: 16
- 1 mg IMP321 LAG-3Ig
- 1.4 mg “Hiltonol” Poly ICLC 50 ml after inoculating the mixed solution (product name) (mixed in physiological saline) into 4 locations near the limbs of the limbs, subcutaneously inoculating 10 times every week for the first 2 months and once every 2 weeks for the next month.
- PBMC peripheral blood mononuclear cells
- Ficoll-Paque Plus density gradient solution GE Healthcare Bio-sciences
- 1x10 6 cells of PBMC per well were placed on a 24-well plate with AIM-V + FBS Cultured in medium.
- rIL2 recombinant IL2
- Novartis 100 units / mL of recombinant IL2 (rIL2; Novartis) is added.
- 10 ⁇ g / mL HSP70 peptide or GPC3 peptide, or HIV peptide (RYLRDQQLL as a negative control) : SEQ ID NO: 42) or EBV peptide (TYGPVFMCL: SEQ ID NO: 43) was added as a positive control, and PBMC culture was continued.
- CD8 + T cells were separated and recovered by negative selection using MACS beads.
- ELISPOT assay was performed using human IFN- ⁇ ELISPOT PLUS kit (Mabtech).
- HLA-A * 24: 02/24: 02 type HLA molecules
- HLA-A * For esophageal cancer patients with HLA molecules of type 02: 06/26: 01, before vaccine administration, 2 mg HSP70 peptide (YGAAVQAAI: SEQ ID NO: 42), 2 mg GPC3 peptide (MVNELFDSL: SEQ ID NO: 43), 1 mg IMP321 (LAG-3Ig), 1.4mg "Hiltonol" (Poly ICLC product name) mixed solution (mixed in physiological saline) divided into 4 locations near the limb groin, 1 month, 2 months and 2 months After weekly subcutaneous inoculations (4 doses, 8 doses and 8 doses), 50 mL of peripheral blood was collected.
- the collected peripheral blood was treated by separation and culture in the same manner as the peripheral blood collected from the above esophageal cancer patients and hepatocellular carcinoma patients, and stained with the same reagents.
- the number of stained spots was counted in the same manner as the method of automatic counting described above. The results are shown in FIGS. 28A, 28B and 28C. After 4 or 8 administrations of HSP70 peptide and GPC3 peptide, the number of spots associated with IFN- ⁇ production increased significantly compared to negative control, confirming that a vaccine-specific immune response occurred .
- SEQ ID NOs: 1 to 15 show the amino acid sequences of HSP70-derived peptides as cancer antigen-derived peptides.
- SEQ ID NOs: 16 to 26 show the amino acid sequences of GPC3-derived peptides as cancer antigen-derived peptides.
- SEQ ID NOs: 27 to 39 show the amino acid sequences of MUC1-derived peptides as cancer antigen-derived peptides.
- SEQ ID NO: 40 shows the amino acid sequence of the P1A peptide.
- SEQ ID NO: 41 shows the amino acid sequence of the gp100 peptide.
- SEQ ID NO: 42 shows the amino acid sequence of the HIV peptide.
- SEQ ID NO: 43 shows the amino acid sequence of the EBV peptide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
すなわち、本発明は、以下のとおりである。
〔1〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
を含む、医薬。
〔2〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、を併用投与するための、〔1〕に記載の医薬。
〔3〕
前記Toll様受容体アゴニストが、Toll様受容体3アゴニスト又はToll様受容体9アゴニストである、〔1〕又は〔2〕に記載の医薬。
〔4〕
前記Toll様受容体アゴニストが、Poly I:C又はその塩である、〔1〕から〔3〕のいずれかに記載の医薬。
〔5〕
前記Poly I:Cが、Poly ICLCである、〔4〕に記載の医薬。
〔6〕
前記LAG-3タンパク質、その変異体、又はその誘導体が、LAG-3タンパク質とIgGの融合タンパク質である、〔1〕から〔5〕のいずれかに記載の医薬。
〔6’〕
少なくとも1種のがん細胞に対する特異的な免疫応答を誘導する物質をさらに含む、〔1〕から〔6〕のいずれかに記載の医薬。
〔6’’〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
少なくとも1種のがん細胞に対する特異的な免疫応答を誘導する物質と、を併用投与するための、〔6’〕に記載の医薬。
〔7〕
少なくとも1種のがん抗原由来ペプチドをさらに含む、〔1〕から〔6〕のいずれかに記載の医薬。
〔8〕
前記少なくとも1種のがん抗原由来ペプチドが、HSP70由来ペプチド又はGPC3由来ペプチドである、〔7〕に記載の医薬。
〔9〕
HSP70由来ペプチド及びGPC3由来ペプチドからなる群から選択される少なくとも1種のがん抗原由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、〔7〕又は〔8〕に記載の医薬。
〔10〕
配列番号7で示されるアミノ酸配列を有するHSP70由来ペプチド又は配列番号16で示されるアミノ酸配列を有するGPC3由来ペプチドを含む、〔9〕に記載の医薬。
〔11〕
2種以上のがん抗原由来ペプチドを含む、〔7〕から〔10〕のいずれかに記載の医薬。
〔12〕
HSP70由来ペプチドと、HSP70由来ペプチド以外のがん抗原由来ペプチドと、を含む、〔11〕に記載の医薬。
〔13〕
GPC3由来ペプチドと、GPC3由来ペプチド以外のがん抗原由来ペプチドと、を含む、〔11〕に記載の医薬。
〔14〕
HSP70由来ペプチドと、GPC3由来ペプチドと、を含む、〔11〕に記載の医薬。
〔15〕
配列番号7で示されるアミノ酸配列を有するHSP70由来ペプチドと、配列番号16で示されるアミノ酸配列を有するGPC3由来ペプチドと、を含む、〔14〕に記載の医薬。
〔16〕
HSP70由来ペプチドと、HSP70由来ペプチド以外のがん抗原由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、〔12〕に記載の医薬。
〔17〕
GPC3由来ペプチドと、GPC3由来ペプチド以外のがん抗原由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、〔13〕に記載の医薬。
〔18〕
HSP70由来ペプチドと、GPC3由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、〔14〕に記載の医薬。
〔19〕
配列番号7で示されるアミノ酸配列を有するHSP70由来ペプチドと、配列番号16で示されるアミノ酸配列を有するGPC3由来ペプチドと、を含む、〔18〕に記載の医薬。
〔20〕
がんワクチン療法に用いられる、〔1〕から〔19〕のいずれかに記載の医薬。
〔21〕
抗がん剤である、〔1〕から〔20〕のいずれかに記載の医薬。
〔22〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
を含むがん細胞に対する特異的な免疫応答の誘導に用いられる、あるいは、がんワクチン療法に用いられるアジュバント。
〔23〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
を含むがん細胞に対する特異的な免疫応答の誘導に用いられる、あるいは、がんワクチン療法に用いられる組合せ。
〔24〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体を、それを必要とする患者に投与する、患者の疾患を治療又は予防する方法。
〔25〕
Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体を、それを必要とする患者に投与する、がん細胞に対する特異的な免疫応答を誘導する方法。
TLRアゴニストとして、TLR1アゴニスト~TLR10アゴニストが挙げられるが、例えば、TLR3アゴニスト、TLR4アゴニスト、TLR7アゴニスト、TLR8アゴニスト、TLR9アゴニスト又はTLR10アゴニストとすることができる。中でも、TLRアゴニストは、TLR3アゴニスト又はTLR9アゴニストであってもよい。
TLR1アゴニストとしては、例えば、lipoprotein、Triacylated lipopeptides、及びZymosan等が挙げられる。
TLR2アゴニストとしては、例えば、SMP-105, Acylated lipopeptides、Amphotericin B、Atypical LPS、Byglican、Forins、Glyco(phospho)lipids、Lipoteichoic acid、Peptidoglycan、Phenol soluble modulin、及びZymosan等が挙げられる。
本発明に用いる場合、Poly I:Cはその塩であってもよく、例えばナトリウム塩とすることができる。また、Poly I:Cとしては、Poly ICLCを用いることもできる。TLR3アゴニストとしては、RIBOXXOLを用いることもできる。
TLR3アゴニストとしては、例えば、Poly I:C、Poly ICLC (製品名「Hiltonol」)、RIBOXXOL、Ampligen、IPH-3102、cM362-139、及びcM362-140等が挙げられる。
TLR3アゴニストとしては、好ましくはPoly I:Cが用いられるが、Poly I:Cの中でも、Poly-LysineとCarboxymethylcelluloseで安定化させたPoly ICLC (製品名「Hiltonol」)が用いられる。
TLR4アゴニストとしては、例えば、MPL、MPLA、OM-174 (CRX-527)、Picibanil (OK-432)、及びONO-4007等が挙げられる。
TLR5アゴニストとしては、例えば、CBLB502等が挙げられる。
TLR6アゴニストとしては、例えば、Diacylated lipopeptides、Lipoproteins、Lipoteichoic acid、及びZymosan等が挙げられる。
また、本明細書において「TLR8アゴニスト」とは、TLR8に結合すると、TLR8に天然のリガンドが結合したときと同じように刺激を与える分子をいう。
TLR7及びTLR8は、ウイルス由来の一本鎖RNAを認識し、自然免疫系を活性化する。TLR7/8アゴニストとしては、Imiquimodが知られているがこれに限定されない。本発明に用いる場合、Imiquimodはその塩であってもよく、例えばナトリウム塩とすることができる。
TLR7/8アゴニストとしては、例えば、Imiquimod (S-26308, R-837)、Resimiquimod (R-848)、3M-052、852A、VTX-1463、VTX-2337、AZD8848 (DSP-3025)、ANA773、及びTMX-101等が挙げられる。
TLR9アゴニストとしては、例えば、CpG、CpG-28、CpG-685 (GNKG168)、CpG-1826、CpG-7909 (PF-3512676, Agatolimod, promune(登録商標))、ODN1585、IMO-2125、IMO-2055 (EMD1201081)、ISS1018、MGN-1703、MGN-1706、AVE0675、QAX-935、SAR-21609、SD-101、及びDIMS0150等のCpG ODNが挙げられる。
TLR10アゴニストとしては、例えば、acylated lipopeptide等が挙げられる。
本明細書において「1又は数個」とは、1個、2個、3個、4個、5個、6個、7個、8個、9個、又は10個を意味する。
LAG-3タンパク質の機能的な誘導体としては、具体的には、LAG-3とIgGとの融合タンパク質であるIMP321 (LAG-3Ig)を好適に用いることができる。
TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の組合せとしては、TLR3アゴニスト又はTLR9アゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の組合せ、あるいは、TLRアゴニストと、LAG-3タンパク質又はLAG-3タンパク質の誘導体の組合せであることが好ましく、TLR3アゴニスト又はTLR9アゴニストと、LAG-3タンパク質又はLAG-3タンパク質の誘導体の組合せであることがより好ましく、TLR3アゴニストと、LAG-3タンパク質又はLAG-3タンパク質の誘導体の組合せであることがさらに好ましく、TLR3アゴニストと、LAG-3タンパク質の誘導体の組合せであることがよりさらに好ましい。
TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の組合せにおいて、TLR3アゴニストとして、Poly I:C又はその塩を用いることができ、Poly I:Cとして、Poly ICLCを用いてもよい。TLR3アゴニストとしては、Poly I:C、Poly ICLC (製品名「Hiltonol」)、RIBOXXOL、Ampligen、IPH-3102、cM362-139、及びcM362-140等を用いてもよい。TLR3アゴニストとしては、好ましくはPoly ICLC (製品名「Hiltonol」)を用いることができる。
TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の組合せにおいて、TLR9アゴニストとして、CpG ODN又はその塩を用いてもよく、CpG ODNのナトリウム塩を用いてもよい。また、TLR9アゴニストとしては、CpG、CpG-28、CpG-685 (GNKG168)、CpG-1826、CpG-7909 (PF-3512676, Agatolimod, promune(登録商標))、ODN1585、IMO-2125、IMO-2055 (EMD1201081)、ISS1018、MGN-1703、MGN-1706、AVE0675、QAX-935、SAR-21609、SD-101、及びDIMS0150等を用いてもよい。
TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の組合せにおいて、LAG-3タンパク質、その変異体、又はその誘導体としては、上述したLAG-3タンパク質、その機能的な変異体、又はその機能的な誘導体を用いることができるが、LAG-3タンパク質の機能的な誘導体を用いてもよく、ヒトLAG-3やLAG-3とIgGとの融合タンパク質(LAG-3Ig)を用いてもよい。
本発明に係る医薬としては、好適には、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体に加え、さらに、がん細胞に対する特異的な免疫応答を誘導する物質を含む。がん細胞に対する特異的な免疫応答を誘導する物質をさらに含む医薬である場合にも、上述したTLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の組合せとすることができる。
本発明に係る医薬として、好適には、TLR3アゴニスト又はTLR9アゴニストと、LAG-3タンパク質又はLAG-3タンパク質の誘導体と、がん細胞に対する特異的な免疫応答を誘導する物質と、を含む。より好適には、本発明に係る医薬は、TLR3アゴニストと、LAG-3タンパク質又はLAG-3タンパク質の誘導体と、がん細胞に対する特異的な免疫応答を誘導する物質と、を含む。さらに好適には、本発明に係る医薬は、TLR3アゴニストと、LAG-3タンパク質の誘導体と、がん細胞に対する特異的な免疫応答を誘導する物質と、を含む。
本発明に係る医薬として、がん細胞に対する特異的な免疫応答を誘導する物質をさらに含む場合、がん細胞に対する特異的な免疫応答を誘導する物質としては、がん抗原タンパク質、がん抗原由来ペプチド、それらをコードする核酸、がん抗原提示細胞、及び腫瘍細胞が用いられてもよく、がん抗原由来ペプチドが好適に用いられる。
本発明に係る医薬においてTLRアゴニストとして、TLR3アゴニストを用いた場合を例に説明すると、TLR3アゴニストと同時に投与されたがん細胞に対する特異的な免疫応答を誘導する物質が抗原提示され、T細胞プライミングが促進される。
本発明に係る医薬においてLAG-3タンパク質、その変異体、又はその誘導体として、LAG-3Igを用いた場合を例に説明すると、がん細胞に対する特異的な免疫応答を誘導する物質に対する抗原提示を促進すると共に、腫瘍局所においては、MHC Class II分子を発現している腫瘍又はマクロファージ等による活性CTLに対する抑制シグナルをブロックすることで、CTLの疲弊を抑制することが期待される。
TLR3アゴニスト及びLAG-3Igの働きにより、同時に投与されるがん細胞に対する特異的な免疫応答を誘導する物質に非依存に腫瘍傷害を亢進すると考えられる。
がん抗原タンパク質としては、特に限定されるものではないが、好適には、HSP70、GPC3、MUC1、及びgp100等が挙げられる。
本発明において、HSP70由来ペプチドが用いられる場合には、特に限定されるものではないが、配列番号1~15のいずれかで表されるアミノ酸配列を有するHSP70由来ペプチドを好適に用いることができ、配列番号7で表されるアミノ酸配列を有するHSP70由来ペプチドがより好適に用いられる。
がん抗原由来ペプチドとしてのGPC3由来ペプチドとしては、特に限定されるものではないが、例えば、国際公開第2016/143816号に記載のペプチドが挙げられ、具体的には、配列番号16~26のいずれかで表されるアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ11以下のアミノ酸残基から成るペプチドが挙げられる。
本発明において、GPC3由来ペプチドが用いられる場合には、特に限定されるものではないが、配列番号16~26のいずれかで表されるアミノ酸配列を有するGPC3由来ペプチドを好適に用いることができ、配列番号16で表されるアミノ酸配列を有するGPC3由来ペプチドがより好適に用いられる。
がん抗原由来ペプチドとしてのMUC1由来ペプチドとしては、特に限定されるものではないが、例えば、国際公開第2016/143814号に記載のペプチドが挙げられ、具体的には、配列番号27~39のいずれかで表されるアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ11以下のアミノ酸残基から成るペプチドが挙げられる。
これら抗原由来ペプチドは、例示として開示されるものであって、本発明に係る医薬に用いられる「がん細胞に対する特異的な免疫応答を誘導する物質」が、これら抗原由来ペプチドに限定されるものではない。
本発明に係る医薬は、好ましくは、少なくとも1種のがん抗原由来ペプチドを含む。
少なくとも1種のがん抗原由来ペプチドとは、特に限定されるものではなく、1種のがん抗原由来ペプチドを用いてもよく、2種以上のがん抗原由来ペプチドを用いてもよい。
がん抗原タンパク質に由来するがん抗原由来ペプチドにおけるがん抗原タンパク質としては、「がん抗原タンパク質」について列記するがん抗原タンパク質から選択されるタンパク質を挙げることができる。
2種以上のがん抗原由来ペプチドとして、異なるがん抗原タンパク質に由来する、2種以上のがん抗原由来ペプチドを用いてもよく、2種以上の、同じがん抗原タンパク質に由来する異なるがん抗原由来ペプチドを用いてもよい。
2種以上の異なるがん抗原タンパク質としては、「がん抗原タンパク質」について列記するがん抗原タンパク質から選択される2種以上の異なるタンパク質を挙げることができる。
具体的には、がん抗原由来ペプチドとして、HSP70、GPC3、MUC1、又はgp100由来ペプチドを用いることが好ましく、HSP70由来ペプチド又はGPC3由来ペプチドを用いることがより好ましい。
本発明に係る医薬が、1種のがん抗原由来ペプチドを含む場合、HSP70由来ペプチド又はGPC3由来ペプチドを用いることが好ましい。
本発明に係る医薬が、2種以上のがん抗原由来ペプチドを含む場合、2種以上のうちの1種として、HSP70、GPC3、MUC1、又はgp100由来ペプチドを用いることが好ましい。
2種のがん抗原由来ペプチドとしては、HSP70由来ペプチドと、HSP70由来ペプチド以外のがん抗原由来ペプチドとの組合せ、GPC3由来ペプチドと、GPC3由来ペプチド以外のがん抗原由来ペプチドとの組合せ、HSP70由来ペプチドと、GPC3由来ペプチドとの組合せ、が好適に用いられる。
HSP70由来ペプチド以外のがん抗原由来ペプチド及びGPC3由来ペプチド以外のがん抗原由来ペプチドとしては、「がん抗原タンパク質」について列記するがん抗原タンパク質から選択されるタンパク質として、それぞれ、HSP70及びGPC3を除いた抗原タンパク質に由来するがん抗原由来ペプチドが挙げられる。
本発明においては、がん抗原由来ペプチドを2種用いる場合、HSP70由来ペプチド及びGPC3由来ペプチドの2種の組合せとすることが好ましい。
1種のがん抗原由来ペプチドを用いる場合、HSP70、GPC3、MUC1、又はgp100由来ペプチドを用いることが好ましく、HSP70由来ペプチド又はGPC3由来ペプチドを用いることが好より好ましい。
また、2種以上の「がん細胞に対する特異的な免疫応答を誘導する物質」は、がん抗原タンパク質、がん抗原由来ペプチド、それらをコードする核酸、がん抗原提示細胞、及び腫瘍細胞から選ばれる2種以上としてもよく、2種のがん細胞に対する特異的な免疫応答を誘導する物質を含む場合を例示して説明すると、1種のがん抗原由来ペプチドと、もう1種のがん抗原由来ペプチドを含んでもよいが、1種のがん抗原由来ペプチドと、がん抗原タンパク質、がん抗原タンパク質又はがん抗原由来ペプチドをコードする核酸、がん抗原提示細胞、及び腫瘍細胞から選ばれる1種を含んでもよい。
本明細書において「アジュバント」は、免疫応答を誘導する物質と一緒に投与されることにより、当該免疫応答の誘導を増強させる分子群を意味する。
本発明においては、LAG-3タンパク質、その変異体、又はその誘導体と併用投与するための、TLRアゴニストを含む医薬であってもよく、TLRアゴニストと併用投与するための、LAG-3タンパク質、その変異体、又はその誘導体を含む医薬であってもよい。
また、本発明においては、がん細胞に対する特異的な免疫応答を誘導する物質と、LAG-3タンパク質、その変異体、又はその誘導体と併用投与するための、TLRアゴニストを含む医薬であってもよく、かかるTLRアゴニストを含む医薬は、LAG-3タンパク質、その変異体、又はその誘導体とアジュバントとして、がん細胞に対する特異的な免疫応答を誘導する物質、好ましくは、がん抗原由来ペプチドに対し、免疫応答の誘導を増強し得る。本発明においては、がん細胞に対する特異的な免疫応答を誘導する物質と、TLRアゴニストと併用投与するための、LAG-3タンパク質、その変異体、又はその誘導体を含む医薬であってもよく、かかるLAG-3タンパク質、その変異体、又はその誘導体を含む医薬は、TLRアゴニストとアジュバントとして、がん細胞に対する特異的な免疫応答を誘導する物質、好ましくは、がん抗原由来ペプチドに対し、免疫応答の誘導を増強し得る。
また、本発明において、抗がん剤である医薬は、有効成分として、がん細胞に対する特異的な免疫応答を誘導する物質、好ましくは、がん抗原由来ペプチドを含み、アジュバントとして、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とを含んでいてもよい。
本発明に係る医薬ががんワクチンとして用いられる場合も経口投与又は非経口投与することができる。非経口投与としては、例えば、腹腔内投与、皮下投与、皮内投与、筋肉内投与、静脈内投与、又は鼻腔内投与を用いることができる。
本発明に係る医薬がペプチドを含む場合、ポリ乳酸・グリコール酸(PLGA)マイクロカプセルや多孔性ヒドロキシアパタイト微粒子等に封入又は吸着させて徐放性を付与してもよく、パルス放出型イオントフォレシス貼付剤システムを利用して経皮吸収させてもよい。
また、本発明に係る医薬が、一の製剤として、がん細胞に対する特異的な免疫応答を誘導する物質、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体と、を含んでいてもよく、それぞれ別の製剤として、すなわち、がん細胞に対する特異的な免疫応答を誘導する物質を含む製剤と、TLRアゴニストを含む製剤と、LAG-3タンパク質、その変異体、又はその誘導体を含む製剤との組合せであってもよい。がん細胞に対する特異的な免疫応答を誘導する物質と、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とを、2種の成分を含む製剤と、残り1種の成分を含む製剤の組合せとしてもよく、3種の成分の組合せとなるのであれば、任意の2種の成分を含む製剤と、任意の2種の成分を含む製剤の組合せとしてもよい。
また、本発明に係る医薬は、キットであってもよい。キットである場合、キットは、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体と、を含いんでいてもよく、がん細胞に対する特異的な免疫応答を誘導する物質と、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体と、を含んでいてもよい。
本発明においては、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体と、それを必要とする患者に投与することにより、患者の疾患を治療又は予防することができる。また、本発明においては、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体と、それを必要とする患者に投与する、がん細胞に対する特異的な免疫応答を誘導する方法をも提供する。
患者の疾患を治療又は予防する場合、あるいは、がん細胞に対する特異的な免疫応答を誘導する方法において、がん細胞に対する特異的な免疫応答を誘導する物質、好ましくは、がん抗原由来ペプチドをさらに投与してもよい。
がん細胞に対する特異的な免疫応答を誘導することにより、がん細胞に対する特異的な免疫応答を誘導する物質、好ましくは、がん抗原由来ペプチドの薬効をより強力に発揮させることができる。
本発明に係る医薬が併用投与されるとは、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とが、患者に投与されていればよく、それぞれ任意の組合せで、同時に、また、別時に投与してもよい。また、本発明に係る医薬ががん細胞に対する特異的な免疫応答を誘導する物質を含む場合には、がん細胞に対する特異的な免疫応答を誘導する物質と、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とを、それぞれ任意の組合せで、同時に、また、別時に投与してもよい。
同時に投与する場合には、一の製剤として同時に投与してもよく、投与時にTLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とを混合して投与製剤として調整して同時に投与してもよい。
別時に投与する場合には、TLRアゴニストを投与した後に、LAG-3タンパク質、その変異体、又はその誘導体を投与してもよく、LAG-3タンパク質、その変異体、又はその誘導体を投与した後に、TLRアゴニストを投与してもよい。
別時に投与する場合には、がん細胞に対する特異的な免疫応答を誘導する物質を投与した後に、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とを、それぞれ同時に又は別時に投与してもよく、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体とを、それぞれ同時に又は別時に投与した後に、がん細胞に対する特異的な免疫応答を誘導する物質を投与してもよく、また、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の一方を投与した後に、がん細胞に対する特異的な免疫応答を誘導する物質を投与し、TLRアゴニストと、LAG-3タンパク質、その変異体、又はその誘導体の他方を投与してもよい。別時に投与する場合には、各成分の特性に応じて、各成分の投与間隔に基づき、すなわち、それぞれの投与レジメンに基づいて投与してもよい。
図1に示すプロトコールにしたがって、がん抗原由来ペプチドを用いたがんワクチンにおける各種アジュバントの効果を比較した。
がんモデルマウスとして、DBA/2マウスにP815細胞(DBA/2マウス由来のマウス肥満細胞腫)を移植して用いた。
がん抗原由来ペプチドとして、P815腫瘍の腫瘍抗原であるP1Aタンパク質の部分配列からなり、MHCのH-2Ld拘束性に提示されることが知られているペプチド(以下「P1Aペプチド」という。)を用いた。P1Aペプチドのアミノ酸配列はLPYLGWLVF(配列番号40)である。
P1A CTLとして、P1Aペプチドを認識するT細胞受容体を発現するT細胞を用いた。実験では、本発明者が所有するP1A-CTLトランスジェニックマウスから脾臓を採取し、TCR Vα8.3(遺伝子導入したTCRのマーカー)にて陽性率を確認し、それに基づいてP1A-CTLの細胞数を決定し、投与した。
アジュバントとしては以下の物質を用いた。
百日咳菌全菌体(PT)(BioFarma, Bandung, Indonesia)
Poly I:C(TLR3アゴニスト)(Invivogen, SanDiego, USA)
CpG(TLR9アゴニスト)(Invivogen, SanDiego, USA)
IFA(不完全フロイントアジュバント)(Seppic, Paris, France)
LAG-3Ig(Adipogen, SanDiego, USA)
DBA/2マウスに1匹当たり5×105細胞のP815腫瘍細胞を皮下接種し、この日をDay 0とした。Day 8に1匹当たり2.5×105細胞のP1A CTLを静脈注射した。Day 9及びDay 16に、1マウス当たり50μgのP1AペプチドとアジュバントをPBS中に混和したものを皮下注射した。
マウスを5匹ずつ9群に分け、それぞれに以下のアジュバントを用いた。
1群:PBS(コントロール)
2群:IFA(50μL/mouse)
3群:PT(1×108/mouse)
4群:Poly I:C(50μg/mouse)
5群:Poly I:C(50μg/mouse)+ CpG(10μg/mouse)
6群:LAG-3Ig(1μg/mouse)
7群:LAG-3Ig(1μg/mouse)+ Poly I:C(50μg/mouse)
Day 7以降のすべてのマウスについての腫瘍サイズ(mm3)の変化を図2~8に示す。
1~6群では、いずれも徐々に腫瘍サイズが増大し、多くのマウスが途中で死亡した。Day 70まで腫瘍サイズが増大することなく生存したマウスは、2、3及び6群では0匹、1及び4群では1匹、5群では3匹であったところ、7群では、5匹すべてのマウスにおいて腫瘍サイズの増大が見られず、Day 115まで生存した。
DBA/2マウスに1匹当たり5×105細胞のP815腫瘍細胞を皮下接種してがんモデルマウスとし、この日をDay 0とした。Day 8に1匹当たり2.5×105細胞のP1A CTLを静脈注射した。Day 9及びDay 14に、1マウス当たり50μgのP1AペプチドとアジュバントをPBS中に混和したものを皮下注射した。各マウスに以下のアジュバントを用いた。
1群:IFA(50μL/mouse)
2群:Poly I:C(50μg/mouse)
3群:LAG-3Ig(1μg/mouse)
4群:LAG-3Ig(1μg/mouse)+ Poly I:C(50μg/mouse)
その後Day21に腫瘍組織を採取し、腫瘍組織切片のプレパラートを作製した後、ヘマトキシリン・エオジン染色により組織像を観察するとともに、細胞核及び免疫細胞(CD4細胞及びCD8細胞)の蛍光染色を行った。
蛍光組織染色は、以下の試薬を用いた。
細胞核:ProLongR Gold Antifade Reagent with DAPI (Invitrogen)
CD4細胞1次抗体:Rat Anti-Mouse CD4 Purified IgG2b. Clone: GK1.5 (eBioscience)
CD4細胞2次抗体:Mouse monoclonal (2B 10A8) Anti-Rat IgG2b heavy chain (Alexa FluorR 647), (abcam)
CD8細胞1次抗体:Rat Anti-Mouse CD8α Purified IgG2a. Clone: 53-6.7 (eBioscience)
CD8細胞2次抗体:Mouse monoclonal (2A 8F4) Anti-Rat IgG2a heavy chain (Alexa FluorR 488) (abcam)
DBA/2マウスに1匹当たり5×105細胞のP815腫瘍細胞を皮下接種してがんモデルマウスとし、この日をDay 0とした。Day 8に1匹当たり2.5×105細胞のP1A CTLを静脈注射した。Day 9及びDay 14に、1マウス当たり50μgのP1AペプチドとアジュバントをPBS中に混和したものを皮下注射した。アジュバントとしては、LAG-3Ig (1μg/mouse) + Poly I:C (50μg/mouse)を用いた。
続いて、P815腫瘍細胞を接種しても腫瘍サイズの増大が見られず、腫瘍を拒絶したと判断されたDBA/2マウス、及び何の処置もしていないナイーブなDBA/2マウスを用いて、再度、1匹当たり1x106細胞のP815腫瘍細胞、又は1匹当たり1x106細胞のL1210腫瘍細胞を皮下接種した。腫瘍を拒絶したと判断されたDBA/2マウスについては、最初のP815細胞接種から115日後(Day115)に、再度腫瘍細胞を接種した。
図10左にL1210細胞接種後のマウスの平均腫瘍サイズ(mm3)の変化を示し、図10右にP815細胞接種後のマウスの平均腫瘍サイズ(mm3)の変化を示す。いずれも○が腫瘍を拒絶したと判断されたDBA/2マウス、●がナイーブなDBA/2マウスである。
ナイーブなDBA/2マウスでは、P815細胞及びL1210細胞のいずれを接種しても腫瘍サイズの増大が見られた。一方、P815細胞による腫瘍増大を拒絶したと判断されたマウスでは、別の腫瘍細胞であるL1210細胞接種に伴う腫瘍サイズの増大が見られたものの、P815細胞接種に伴う腫瘍サイズの増大は観察されず、マウス側に同一腫瘍に対する拒絶能が維持されていることが確認された。
DBA/2マウスに1匹当たり5×105細胞のP815腫瘍細胞を皮下接種しがんモデルマウスとし、この日をDay 0とした。Day 8に1匹当たり2.5×105細胞のP1A CTLを静脈注射した。Day 9及びDay 14に、1マウス当たり50μgのP1AペプチドとアジュバントをPBS中に混和したものを皮下注射した。各マウスに以下のアジュバントを用いた。
1群:IFA(50μL/mouse)
2群:Poly I:C(50μg/mouse)
3群:LAG-3Ig(1μg/mouse)
4群:LAG-3Ig(1μg/mouse)+ Poly I:C(50μg/mouse)
その後Day21に、腋窩又は鼠径部のリンパ節のうち腫瘍部位に近いリンパ節を採取し、分離した免疫細胞1.5x105個と、100Gy放射線照射したP815細胞4x104個を、3日間共培養した。
免疫細胞増殖能は、3H-thymidine;37KBq/wellを培養上清中に添加し、4時間後に細胞取り込まれた3H-thymidineの放射活性を測定することにより測定した。
細胞上清中のサイトカイン量は、Bio-Plex Pro mouse cytokine 23-Plex Immunoassay kit (BIO-RAD)を用いて測定した。
免疫細胞増殖能の測定結果を図11Aに、サイトカイン等の測定結果を図11Bに示す。
アジュバントとしてLAG-3Igとpoly I:Cを組み合わせた場合に、免疫細胞増殖能の増大が観察された。また、サイトカイン等のうち、アジュバントとしてLAG-3Igとpoly I:Cを組み合わせた場合に、IFN-γ、GM-CSF、IL-4、IL-5、IL-17Aの産生が増加していることが分かった。
DBA/2マウスに1匹当たり5×105細胞のP815腫瘍細胞を皮下接種してがんモデルマウスとし、この日をDay 0とした。Day 8に1匹当たり2.5×105細胞のP1A CTLを静脈注射した。Day 9及びDay 14に、1マウス当たり50μgのP1AペプチドとアジュバントをPBS中に混和したものを皮下注射した。各マウスに以下のアジュバントを用いた。
1群:IFA(50μL/mouse)
2群:Poly I:C(50μg/mouse)
3群:LAG-3Ig(1μg/mouse)
4群:LAG-3Ig(1μg/mouse)+ Poly I:C(50μg/mouse)
その後Day21に、腋窩又は鼠径部のリンパ節のうち腫瘍部位に近いリンパ節を採取し、CD8及びVα8.3発現陽性の細胞群(キラーT細胞)、又はCD4及びVα8.3発現陽性の細胞群(ヘルパーT細胞)を回収した。
細胞(CD4細胞及びCD8細胞)の細胞表面マーカー分子であるPD-1、BTLA、TIGIT、及びLAG-3の発現量を測定した。細胞表面マーカー分子に対する抗体として、以下のものを用いた。
PD-1:Anti-Mouse CD279 (PD-1) PE. Clone: J43 (eBioscience)
BTLA:Anti-Mouse CD272 (BTLA) PE. Clone: 8F4 (eBioscience)
TIGIT:PE anti-mouse TIGIT (Vstm3) Antibody. Clone: 1G9 (BioLegend)
LAG-3:Anti-Mouse CD223 (Lag-3) PE. Clone: eBioC9B7W (C9B7W) (eBioscience)
CD8細胞の結果を図12Aに示し、CD4細胞の結果を図12Bに示す。
アジュバントとしてLAG-3IgとPoly I:Cを組み合わせた場合に、CD4陽性細胞及びCD8陽性細胞のともに、PD-1、TIGIT、LAG-3については顕著な発現量の減少が見られたが、BTLAの発現量の減少は少なかった。
C57BL/6マウスに1匹当たり1×105個のB16-F10メラノーマ細胞を皮下接種してがんモデルマウスとし、この日をDay 0とした。Day 8に1マウス当たり50μgのgp100ペプチドとアジュバントをPBS中に混和したものを皮下注射した。各マウスに以下のアジュバントを用いた。gp100ペプチドのアミノ酸配列はKVPRNQDWL(配列番号41)である。
1群:IFA(50μL/mouse)
2群:Poly I:C(50μg/mouse)
3群:LAG-3Ig(1μg/mouse)
4群:LAG-3Ig(1μg/mouse)+ Poly I:C(50μg/mouse)
その後Day 14に、腋窩又は鼠径部のリンパ節のうち腫瘍部位に近いリンパ節(あるいはその両方のリンパ節)を採取し、分離した免疫細胞を1ウェルあたり3x105個にて、10、5、2.5、又は0μg/mLのgp100ペプチド存在下で培養した。
免疫細胞増殖能は、3H-thymidine;37KBq/wellを培養上清中に添加し、3日間の培養期間中の最後の10時間の間に細胞取り込まれた3H-thymidineの放射活性を測定することにより測定した。
10μg/mLのgp100ペプチド存在下で3日間培養した細胞上清中のIFN-γ産生量は、Bio-Plex Pro mouse cytokine 23-Plex Immunoassay kit (BIO-RAD)を用いて測定した。
免疫細胞増殖能の測定結果を図13Aに、IFN-γ産生量の測定結果を図13Bに示す。
図13Aにおいて、○が1群、■が2群、□が3群、●が4群の結果を示す。
B16-F10メラノーマ接種モデルマウス系を用いた場合でも、アジュバントとしてLAG-3IgとPoly I:Cを組み合わせた場合に、gp100腫瘍抗原特異的な免疫細胞増殖能の増大及びIFN-γ産生量の増加が観察された。
腫瘍モデル系及び免疫抗原となるペプチドの種類によらず、アジュバントとしてLAG-3IgとPoly I:Cを組み合わせた場合に、顕著な免疫系の活性効果を発揮することが確認された。
アジュバントとしては以下の物質を用いた。
Poly I:C(TLR3アゴニスト)(Invivogen, SanDiego, USA)
RIBOXXOL (TLR3アゴニスト) (Riboxx, Radebeul, Germany)
MPL (TLR4アゴニスト) (Invivogen, SanDiego, USA)
Imiquimod (TLR7/8アゴニスト) (Invivogen, SanDiego, USA)
CpG(TLR9アゴニスト)(Invivogen, SanDiego, USA)
LAG-3Ig(Adipogen, SanDiego, USA)
DBA/2マウスに1匹当たり5×105細胞のP815腫瘍細胞を皮下接種してがんモデルマウスとし、この日をDay 0とした。Day 7に1匹当たり2.5×105細胞のP1A CTLを静脈注射した。Day 8及びDay 15に、1マウス当たり50μgのP1AペプチドとアジュバントをPBS中に混和したものを皮下注射した。マウスを4匹又は5匹ずつ9群に分け、それぞれに以下のアジュバントを用いた。
1群:P1Aペプチドのみ(コントロール)
2群:Poly I:C(50μg/mouse)
3群:Poly I:C(50μg/mouse)+ LAG-3Ig(1μg/mouse)
4群:P1Aペプチドなし、Poly I:C(50μg/mouse)+ LAG-3Ig(1μg/mouse)のみ
5群:RIBOXXOL(100μg/mouse)
6群:RIBOXXOL(100μg/mouse)+ LAG-3Ig(1μg/mouse)
7群:MPL(10μg/mouse)+ LAG-3Ig(1μg/mouse)
8群:Imiquimod(50μg/mouse)+ LAG-3Ig(1μg/mouse)
9群:CpG(10μg/mouse)+ LAG-3Ig(1μg/mouse)
Day 7以降のすべてのマウスについての腫瘍サイズ(mm3)の変化を図14~22に示す。
1群ではDay40までに5匹中5匹全てが死亡したが、2群では5匹中4匹が、3群では5匹中5匹が、6群では5匹中3匹が、4~5群では5匹中2匹が、7~9群では5匹中1匹が生存し、さらに、3群では5匹中4匹、6群では5匹中3匹がDay66まで生存した。2群と3群、5群と6群とを比較することにより、アジュバントの併用効果が示された。
C57BL/6マウスに1匹当たり1×105個のB16-F10メラノーマ細胞を皮下接種してがんモデルマウスとし、この日をDay0とした。Day5及びDay12の計2回、1マウス当たり50μgのgp100ペプチドとアジュバントをPBS中に混和したものを皮下注射した。各マウスに以下のアジュバントを用いた。
1群:IFA(50μL/mouse)
2群:Poly I:C(50μg/mouse)
3群:LAG-3Ig(1μg/mouse)
4群:LAG-3Ig(1μg/mouse)+ Poly I:C(50μg/mouse)
Day 5以降のすべてのマウスについての腫瘍サイズ(mm3)の変化を図23~26に示す。
各群5匹のマウスは、1群ではDay31、2群ではDay35、3群ではDay37で5匹全てが死亡した一方、4群ではDay57で死亡した。1群に比較して、2及び3群では有意な生存期間の延長効果は認められなかったが、4群では1、2及び3群の全てに対して、有意な生存期間の延長が確認された。
HLA-A*02:07/24:02型のHLA分子を持つ食道がん患者及びHLA-A*24:02/26:01型のHLA分子を持つ肝細胞がん患者に対し、2mg HSP70 peptide (YGAAVQAAI:配列番号7)、2mg GPC3 peptide (MVNELFDSL:配列番号16)、 1mg IMP321 (LAG-3Ig)、 1.4mg 「Hiltonol」 (Poly ICLCの製品名)の混合溶液(生理食塩水中に混和)を、四肢鼠径部近傍4カ所に分けて、最初の2ヶ月間は毎週、翌月は2週間に1回の合計10回皮下接種した後、50mLの末梢血を採取した。
末梢血からFicoll-Paque Plus density gradient solution (GE Healthcare Bio-sciences)を用いてPBMC(末梢血単核球)を分離し、24 well plateに1 wellあたり1x106cellのPBMCをAIM-V+FBS培地で培養した。
Day1、 Day4、 Day8及びDay12には100 units/mL of recombinant IL2 (rIL2; Novartis)を添加するとともに、Day0及びDay7には10μg/mLのHSP70 peptide、又はGPC3 peptide、又はネガティブコントロールとしてHIV peptide (RYLRDQQLL:配列番号42)、又はポジティブコントロールとしてEBV peptide (TYGPVFMCL:配列番号43)を添加し、PBMCの培養を継続した。Day14に、MACS beadsを用いたネガティブセレクションで、CD8+T細胞を分離回収した。
human IFN-γ ELISPOT PLUS kit(Mabtech)を用いて、ELISPOTアッセイを行った。あらかじめ抗IFN-γ抗体でコーティングした12 well plateを用いて、2x104cells /wellの腫瘍細胞をstimulatorとして、1x104cells /wellのCD8+ T responder細胞と共に37℃、48時間共培養した。
ビオチン化した抗IFN-γ抗体 (7-B6-1)を2次抗体として添加し2時間培養した後、HRP(Horse Raddish Peroxidase)試薬を添加し、さらにTMB(tetramethylbenzidine)試薬を用いて染色を行った。
染色されたスポット数は、the ImmunoSPOT S4(Cellular Technology Ltd)を用いて自動カウントした。
結果を図27A、図27Bに示す。
HSP70ペプチド及びGPC3ペプチドを合計10回投与した後、ネガティブコントロールに対してIFN-γ産生に伴うスポット数が優位に増加しており、ワクチン特異的な免疫反応が起こっていることが確認できる。
採取した末梢血をそれぞれ、上記の食道がん患者及び肝細胞がん患者から採取した末梢血と同様に分離や培養によって処理し、同様の試薬により染色を行った。染色されたスポット数を、上記で自動カウントした方法と同様にカウントした。
結果を、図28A、図28B及び図28Cに示す。
HSP70ペプチド及びGPC3ペプチドを4回または8回投与した後、ネガティブコントロールに対してIFN-γ産生に伴うスポット数が優位に増加しており、ワクチン特異的な免疫反応が起こっていることが確認できる。
配列番号16~26は、がん抗原由来ペプチドとしてのGPC3由来ペプチドのアミノ酸配列を示す。
配列番号27~39は、がん抗原由来ペプチドとしてのMUC1由来ペプチドのアミノ酸配列を示す。
配列番号40は、P1Aペプチドのアミノ酸配列を示す。
配列番号41は、gp100ペプチドのアミノ酸配列を示す。
配列番号42は、HIVペプチドのアミノ酸配列を示す。
配列番号43は、EBVペプチドのアミノ酸配列を示す。
Claims (23)
- Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
を含む医薬。 - Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、を併用投与するための、請求項1に記載の医薬。 - 前記Toll様受容体アゴニストが、Toll様受容体3アゴニスト又はToll様受容体9アゴニストである、請求項1又は2に記載の医薬。
- 前記Toll様受容体アゴニストが、Poly I:C又はその塩である、請求項1から3のいずれか1項に記載の医薬。
- 前記Poly I:Cが、Poly ICLCである、請求項4に記載の医薬。
- 前記LAG-3タンパク質、その変異体、又はその誘導体が、LAG-3タンパク質とIgGの融合タンパク質である、請求項1から5のいずれか1項に記載の医薬。
- 少なくとも1種のがん抗原由来ペプチドをさらに含む、請求項1から6のいずれか1項に記載の医薬。
- 前記少なくとも1種のがん抗原由来ペプチドが、HSP70由来ペプチド又はGPC3由来ペプチドである、請求項7に記載の医薬。
- HSP70由来ペプチド及びGPC3由来ペプチドからなる群から選択される少なくとも1種のがん抗原由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、請求項7又は8に記載の医薬。 - 配列番号7で示されるアミノ酸配列を有するHSP70由来ペプチド又は配列番号16で示されるアミノ酸配列を有するGPC3由来ペプチドを含む、請求項9に記載の医薬。
- 2種以上のがん抗原由来ペプチドを含む、請求項7から10のいずれか1項に記載の医薬。
- HSP70由来ペプチドと、HSP70由来ペプチド以外のがん抗原由来ペプチドと、を含む、請求項11に記載の医薬。
- GPC3由来ペプチドと、GPC3由来ペプチド以外のがん抗原由来ペプチドと、を含む、請求項11に記載の医薬。
- HSP70由来ペプチドと、GPC3由来ペプチドと、を含む、請求項11に記載の医薬。
- 配列番号7で示されるアミノ酸配列を有するHSP70由来ペプチドと、配列番号16で示されるアミノ酸配列を有するGPC3由来ペプチドと、を含む、請求項14に記載の医薬。
- HSP70由来ペプチドと、HSP70由来ペプチド以外のがん抗原由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、請求項12に記載の医薬。 - GPC3由来ペプチドと、GPC3由来ペプチド以外のがん抗原由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、請求項13に記載の医薬。 - HSP70由来ペプチドと、GPC3由来ペプチドと、
Poly ICLCと、
LAG-3タンパク質又はLAG-3タンパク質とIgGの融合タンパク質と、を含む、請求項14に記載の医薬。 - 配列番号7で示されるアミノ酸配列を有するHSP70由来ペプチドと、配列番号16で示されるアミノ酸配列を有するGPC3由来ペプチドと、を含む、請求項18に記載の医薬。
- がんワクチン療法に用いられる、請求項1から19のいずれか1項に記載の医薬。
- 抗がん剤である、請求項1から20のいずれか1項に記載の医薬。
- Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
を含むがん細胞に対する特異的な免疫応答の誘導に用いられるアジュバント。 - Toll様受容体アゴニストと、
LAG-3タンパク質、その変異体、又はその誘導体と、
を含むがん細胞に対する特異的な免疫応答の誘導に用いられる組合せ。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES17859460T ES2972560T3 (es) | 2016-10-11 | 2017-04-14 | Medicamento que comprende un agonista de receptores tipo Toll, proteína LAG-3, un péptido derivado de HSP70 y un péptido derivado de GPC3 |
RU2019113989A RU2759728C2 (ru) | 2016-10-11 | 2017-04-14 | Лекарственное средство |
EP17859460.2A EP3527216B1 (en) | 2016-10-11 | 2017-04-14 | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
BR112019006075A BR112019006075A2 (pt) | 2016-10-11 | 2017-04-14 | medicamento |
JP2018544679A JP6998880B2 (ja) | 2016-10-11 | 2017-04-14 | 医薬 |
CA3039033A CA3039033A1 (en) | 2016-10-11 | 2017-04-14 | Medicine |
US16/341,415 US11291718B2 (en) | 2016-10-11 | 2017-04-14 | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
AU2017342189A AU2017342189B2 (en) | 2016-10-11 | 2017-04-14 | Medicine |
CN201780062815.4A CN109982711A (zh) | 2016-10-11 | 2017-04-14 | 药物 |
US17/680,719 US11759518B2 (en) | 2016-10-11 | 2022-02-25 | Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-200227 | 2016-10-11 | ||
JP2016200227 | 2016-10-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/341,415 A-371-Of-International US11291718B2 (en) | 2016-10-11 | 2017-04-14 | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
US17/680,719 Division US11759518B2 (en) | 2016-10-11 | 2022-02-25 | Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018070069A1 true WO2018070069A1 (ja) | 2018-04-19 |
Family
ID=61905333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/015227 WO2018070069A1 (ja) | 2016-10-11 | 2017-04-14 | 医薬 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11291718B2 (ja) |
EP (1) | EP3527216B1 (ja) |
JP (1) | JP6998880B2 (ja) |
CN (1) | CN109982711A (ja) |
AU (1) | AU2017342189B2 (ja) |
BR (1) | BR112019006075A2 (ja) |
CA (1) | CA3039033A1 (ja) |
ES (1) | ES2972560T3 (ja) |
RU (1) | RU2759728C2 (ja) |
TW (1) | TW201813664A (ja) |
WO (1) | WO2018070069A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021106978A1 (ja) | 2019-11-27 | 2021-06-03 | サイトリミック株式会社 | 医薬組成物 |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
US11491204B2 (en) | 2015-04-07 | 2022-11-08 | Cytlimic Inc. | Composition comprising poly I:C and LAG-3-IGG fusion protein |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3269733T3 (da) * | 2015-03-09 | 2020-07-27 | Cytlimic Inc | Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015168379A2 (en) * | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
WO2016056596A1 (ja) * | 2014-10-07 | 2016-04-14 | 日本電気株式会社 | Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
WO2016143816A1 (ja) * | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
WO2016163489A1 (ja) * | 2015-04-07 | 2016-10-13 | 日本電気株式会社 | 医薬 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Hla結合性オリゴペプチド及びそれを含有する免疫調節剤 |
RS50101B (sr) * | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
EA006972B1 (ru) | 1998-12-23 | 2006-06-30 | Пфайзер Инк. | Моноклональное антитело человека к ctla-4 и способы его применения |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
ES2326114T3 (es) | 2000-09-13 | 2009-10-01 | Multimmune Gmbh | Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo. |
WO2003011895A2 (en) | 2001-07-31 | 2003-02-13 | Soederstroem Karl Petter | Compositions and methods for modulation of immune responses |
AU2003254950A1 (en) | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
AU2006248725A1 (en) | 2005-05-19 | 2006-11-23 | Glaxosmithkline Biologicals S.A. | Vaccine composition comprising B-subunit of E. coli heat toxin and an atigen and an adjuvant |
RU2395519C2 (ru) | 2005-08-09 | 2010-07-27 | Онкотерапи Сайенс, Инк. | Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их |
CN101448938A (zh) | 2006-03-28 | 2009-06-03 | 佐藤升志 | 新肿瘤抗原肽 |
RU2333767C2 (ru) | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
CN101311270A (zh) * | 2006-08-18 | 2008-11-26 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的真核表达载体及其疫苗 |
EP2476697B1 (en) | 2006-10-17 | 2015-06-17 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing MPHOSPH1 polypeptides |
WO2008106491A2 (en) | 2007-02-27 | 2008-09-04 | University Of Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
JP2010532785A (ja) | 2007-07-06 | 2010-10-14 | ウニベルジテイト・ウトレヒト・ホールディング・ビー.ブイ. | 炎症性疾患および自己免疫疾患の治療および予防 |
JP2010538655A (ja) | 2007-09-12 | 2010-12-16 | アナフォア インコーポレイテッド | 自己免疫疾患についてのhsp70に基づく治療 |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
ES2457518T3 (es) | 2009-10-06 | 2014-04-28 | Panacela Labs, Inc. | Uso de receptores semejantes a Toll y agonista para tratar cáncer |
MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
WO2012139094A2 (en) * | 2011-04-08 | 2012-10-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of developing a vaccine using peptide-poly ic complexes |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
KR20140143361A (ko) * | 2012-02-02 | 2014-12-16 | 캘리포니아 스템 셀, 인코포레이티드 | 다능성 배엽층 기원 항원 제시 암 백신 |
CN104203277A (zh) | 2012-02-07 | 2014-12-10 | 拉霍拉敏感及免疫学研究所 | 梯牧草变应原和用于调节免疫反应的方法和用途 |
US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
WO2013143026A1 (en) | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
CA2840954A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
SI2961388T1 (sl) | 2013-03-01 | 2019-10-30 | Astex Pharmaceuticals Inc | Kombinacije zdravil |
US11065331B2 (en) | 2016-07-27 | 2021-07-20 | Advanced Innovation Development Co. Ltd. | Immune adjuvant for cancer |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
-
2017
- 2017-04-14 US US16/341,415 patent/US11291718B2/en active Active
- 2017-04-14 BR BR112019006075A patent/BR112019006075A2/pt not_active IP Right Cessation
- 2017-04-14 WO PCT/JP2017/015227 patent/WO2018070069A1/ja unknown
- 2017-04-14 TW TW106112505A patent/TW201813664A/zh unknown
- 2017-04-14 JP JP2018544679A patent/JP6998880B2/ja active Active
- 2017-04-14 CN CN201780062815.4A patent/CN109982711A/zh active Pending
- 2017-04-14 RU RU2019113989A patent/RU2759728C2/ru active
- 2017-04-14 ES ES17859460T patent/ES2972560T3/es active Active
- 2017-04-14 CA CA3039033A patent/CA3039033A1/en not_active Abandoned
- 2017-04-14 EP EP17859460.2A patent/EP3527216B1/en active Active
- 2017-04-14 AU AU2017342189A patent/AU2017342189B2/en active Active
-
2022
- 2022-02-25 US US17/680,719 patent/US11759518B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015168379A2 (en) * | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
WO2016056596A1 (ja) * | 2014-10-07 | 2016-04-14 | 日本電気株式会社 | Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
WO2016143816A1 (ja) * | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
WO2016163489A1 (ja) * | 2015-04-07 | 2016-10-13 | 日本電気株式会社 | 医薬 |
Non-Patent Citations (1)
Title |
---|
KANO Y ET AL.: "Combined adjuvants of pol(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion", CANCER SCI., vol. 107, no. 4, April 2016 (2016-04-01), pages 398 - 406, XP055475305, ISSN: 1347-9032, DOI: doi:10.1111/cas.12861 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11491204B2 (en) | 2015-04-07 | 2022-11-08 | Cytlimic Inc. | Composition comprising poly I:C and LAG-3-IGG fusion protein |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
US11759518B2 (en) | 2016-10-11 | 2023-09-19 | Nec Corporation | Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
WO2021106978A1 (ja) | 2019-11-27 | 2021-06-03 | サイトリミック株式会社 | 医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US11291718B2 (en) | 2022-04-05 |
JP6998880B2 (ja) | 2022-02-10 |
JPWO2018070069A1 (ja) | 2019-09-26 |
RU2019113989A3 (ja) | 2020-11-13 |
ES2972560T3 (es) | 2024-06-13 |
TW201813664A (zh) | 2018-04-16 |
CN109982711A (zh) | 2019-07-05 |
BR112019006075A2 (pt) | 2019-06-18 |
AU2017342189B2 (en) | 2023-09-21 |
EP3527216A4 (en) | 2020-04-01 |
EP3527216A1 (en) | 2019-08-21 |
US20200038508A1 (en) | 2020-02-06 |
RU2759728C2 (ru) | 2021-11-17 |
US11759518B2 (en) | 2023-09-19 |
AU2017342189A1 (en) | 2019-05-02 |
EP3527216B1 (en) | 2024-02-14 |
RU2019113989A (ru) | 2020-11-13 |
US20220175915A1 (en) | 2022-06-09 |
CA3039033A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11759518B2 (en) | Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein | |
US11491204B2 (en) | Composition comprising poly I:C and LAG-3-IGG fusion protein | |
JP6254251B2 (ja) | がんの処置におけるサバイビンワクチンの有効性を向上させるための方法 | |
ES2900262T3 (es) | Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular | |
US20220401540A1 (en) | Pharmaceutical composition | |
JP2018070629A (ja) | がんの処置におけるサバイビンワクチンの有効性を向上させるための方法 | |
Jin et al. | Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17859460 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018544679 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3039033 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019006075 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017342189 Country of ref document: AU Date of ref document: 20170414 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017859460 Country of ref document: EP Effective date: 20190513 |
|
ENP | Entry into the national phase |
Ref document number: 112019006075 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190327 |